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1 Summary
1.1 Summary in English
Since the last ten to twenty years, the cost of sequencing the human genome decreased
continuously. Therefore the interest in RNA sequencing (RNA-Seq) rose as it can be used
to discover the molecular mechanisms behind gene expression profiles of cells in different
healthy or disease states (Wang et al., 2009). The intention of this dissertation is two-fold,
first identify the best performing bioinformatical methods for RNA-Seq analysis at hand
and based on this knowledge generate a standardised workflow, which then could be used
within the MetastaSys consortium. Second, answering the question: Is it possible to detect
somatic mutations in cancer based on RNA-Seq data reliably? This was of particular interest
as the RNA-Seq data was already created for differential gene expression analysis. Getting
further information on mutation status without the need to recreate the data for Exome-Seq
would, on the one hand, save the expensive costs for Exome-Seq and would, on the other
hand, save precious biological material of cancer metastases patients, which are precious to
the physicians.
For the RNA-Seq workflow identification data based on the microarray and Illumina RNA-Seq
platforms were created. Therefore two data sets were created: human patient data from
rectal cancer metastases in the liver and human cell lines from Burkitt’s Lymphoma, which
was stimulated with the B-Cell activating factor BAFF. The advantages of RNA-Seq over
Microarray became clear during the comparative analysis in the first publication (see 3.1).
The primary focus was the performance evaluation of bioinformatical methods based on the
given data sets. The workflow performance was evaluated during the alignment, transcript
quantification, differential gene expression analysis, and functional profiling steps. Results
showed, that despite the workflow with TopHat2 and Cuﬄinks, all workflows achieved nearly
equally good results with a slight preference for STAR and RSEM, as STAR achieved the
overall highest mapping rate and RSEM incorporated multi-mapped reads for quantification
and was also capable of quantifying transcript isoforms next to genes. Afterwards, the best
performing workflow pipeline was applied to mice in another study (see 3.3). The mice
developed metastases in the liver from colorectal cancer. The bioinformatical approach
streamlined via the workflow helped a lot in interpreting the biology behind the expression
of metastasis enhancing genes. It was possible to show links of metastasis-related genes
and their stimulation via the liver environment. These genes were associated with tissue
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remodelling, cell proliferation, adhesion, wnt activity, transcription/regulation, and inhibition
of apoptosis.
The question if a reliable identification of somatic mutation is possible in RNA-Seq is tackled
by implementing Wileup, a program is written in Perl. Wileup’s performance was evaluated
against the state-of-the-art somatic variant caller Mutect2 from the GATK tool suite for
matched RNA-Seq and Exome-Seq samples of 14 patients with either brain (seven patients)
or liver (seven patients) metastases (see 3.2). Results showed that Wileup was capable of
finding all somatic mutations in RNA-Seq identified by Mutect2 in Exome-Seq. In contrast,
Mutect2 and Wileup identified unique germline mutation only found in either of the methods.
These could be explained due to a lack of expression on the RNA-Seq data or due to too
high duplication level in the Exome-Seq data. Furthermore, the somatic mutations could be
independently validated by pathological annotation data. For the uniquely found germline
mutations of either method, it was possible to verify all of them, as they were re-identified in
the Exome-sequenced blood samples of the corresponding patients.
In conclusion, the presented studies in this thesis contribute towards establishing pipeline
standards in transcriptomics, with the focus on differential expression analysis (DEA), and
exploring the capabilities of mutation calling in RNA-Seq.
1.2 Zusammenfassung in Deutsch
Seit ca. 10 bis 20 Jahren reduzieren sich die Kosten zur Sequenzierung eines ganzen
menschlichen Genoms stetig. Gleichzeitig stieg, aufgrund der Seqquenzier-Mo¨glichkeiten das
Interesse, die molekularen Mechanismen hinter den Genexpressionprofilen besser zu verstehen
rapide. Die Intention dieser Dissertation war zweigeteilt,
1: die Identifizierung der am besten geeigneten bioinformatischen Methoden fu¨r die
RNA-Seq Analyse. Dieses Wissen wurde dann zur Etablierung eines standardisierten Ar-
beitsablaufes (im Folgenden Workflow genannt) genutzt, welches im Rahmen des MetastaSys
Verbundprojektes angewandt werden konnte.
2: ”Ist es zuverla¨ssig mo¨glich somatische Mutationen auch in RNA-Seq Daten zu detek-
tieren?”. Diese Frage war von speziellem Interesse, da RNA-Seq Daten von Patienten prima¨r
zur differenziellen Genexpressionsanalyse erzeugt werden sollten. Ko¨nnte man jetzt weiterhin
den Mutatationstatus der Patienten basierend auf diesen Daten ermitteln ohne die Daten
neu mittels Exome-Seq sequenzieren zu mu¨ssen? Dies wu¨rde auf der einen Seite die weitaus
ho¨heren Kosten massiv reduzieren und auf der anderen Seite auch wertvolles biologisches
Biopsie-Material zuru¨ckhalten, welches sonst fu¨r mo¨gliche zuku¨nftige Analysen aufgebraucht
wa¨re.
Zur Identifizierung des optimalen RNA-Seq Workflows wurden Daten basierend auf Microar-
rays und RNA-Seq erhoben. Diese setzten sich aus zwei Datensa¨tzen zusammen: Zum Einen
metastasiertem menschlichen Lebergewebe von Patienten mit Rektumkarzinom, welches in
der Leber Metastasen gebildet hatte und zum Anderen aus humanen Zelllinien von einem
Burkitt’s Lymphom, das mit dem B-Zellen aktivierenden Faktor BAFF stimuliert wurde.
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Die Vorzu¨ge der Analyse von RNA-Seq Daten gegenu¨ber Microarray basierenden wurden
schon fru¨h sichtbar. Dies war der Anlass den Fokus weg von einer vergleichenden Publikation
zwischen Micrarray und RNA-Seq Daten hin zu der Evaluation bioinformatischer Metho-
den zu verschieben (siehe 3.1). Die Methoden wurden an folgenden Arbeitsschritten des
Workflows evaluiert:
• wa¨hrend der Zuordnung der Rohdaten in Form von Millionen von kurzen Sequenzstu¨cken
(reads) zu einer Referenz (z. Bsp. dem menschlichen Genom),
• wa¨hrend dem Za¨hlen der reads, welche Gene u¨berlappen und so die Expression des
Gens abbilden,
• wa¨hrend der statistischen Analyse der Expressionsdifferenz zwischen Gruppen dieser
Gene und
• anschliessender Analyse zugrunde liegender funktionaler genetischer Gruppen.
Resultierend kann gesagt werden, dass mit Ausnahme des Workflows bestehend aus TopHat2
und Cuﬄinks, allen in der Publikation beschriebenen Workflows gelungen ist, a¨hnlich gute
Resultate zu erzielen. Dabei konnte sich der Workflow mit STAR und RSEM leicht gegenu¨ber
den anderen Workflows hervorheben. Dies erkla¨rt sich damit, dass STAR die ho¨chste
Gesamt-Zuordnungsrate der Rohdaten erreichte und RSEM den ho¨chsten Anteil bei der
Genzuordnung verarbeiten konnte. Parallel dazu konnte RSEM die Genexpression auf die
jeweilig zugeho¨rigen Transkripte aufteilen. Nachdem STAR und RSEM als Workflow im
Verbundprojekt festgelegt wurden, wurden diese unter anderem auf Maus-Daten aus dem
Verbundprojekt erfolgreich angewandt und die Ergebnisse publiziert (siehe hierfu¨r 3.3).
Die Ma¨use entwickelten nach einer Injektion kolorektaler Krebszelllen u¨ber die Pfortader
kolorektale Metastasen in der Leber. Der etablierte bioinformatische Workflow konnte nun
massiv die Interpretation der Biologie hinter der Expression von Metastasen versta¨rkenden
Genen unterstu¨tzen und voranbringen. So konnte die Verbindung zwischen Metastasen
unterstu¨tzenden Genen und ihrer Stimulation durch die Leberumgebung gezeigt werden.
Eine Auswahl dieser Gene wurden mit Gewebe Umbau, Zell-Proliferation, Adhesion, Wnt
Aktivita¨t, Transkription/Regulation, sowie der Inhibition der Apoptose, dem kontrollierten
Zelltod assoziiert.
Um die Frage anzugehen, ob es mo¨glich ist somatische Mutationen zuverla¨ssig in RNA-Seq
zu detektieren, wurde Wileup, ein Programm in Perl, implementiert. Wileup’s Ergebnisse
wurden dann mit dem state-of-the-art Programm Mutect2 aus dem GATK Programmkat-
alog verglichen. Dieses wurde explizit fu¨r die Detektion von somatischen Mutationen in
Krebsgewebe entworfen. Es beno¨tigte allerdings Exome-Seq Daten, sowie zusa¨tzlich zum
sequenzierten Tumor-Gewebe eine Normal-Referenz als Abgleich. Damit von Wileup verar-
beitete RNA-Seq Daten Mutect2 verarbeitete Exome-Seq Daten verglichen werden konnten,
wurde ein experimentelles Design gewa¨hlt, das aus 14 Patienten bestand: Jeweils sieben
Patienten mit kolorektalen Gehirnmetastasen und sieben kolorektalen Lebermetastasen. Von
jedem Patienten wurden drei Sequenzierungen vorgenommen: zwei Exom-Sequenzierungen
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vom Blut und dem Metastasengewebe des Patienten und eine RNA Sequenzierung des Metas-
tasengewebes (siehe 3.2). Im Vergleich wurde Mutect2 einmal mit Normalgewebereferenz
und einmal ohne benutzt, was einerseits die optimale Methode widerspiegelte und anderseits
vergleichbarer mit Wileup war, welches auch ohne Normalreferenz angewandt wurde. Die
detektieren somatischen Mutationen konnten in allen drei Methoden einheitlich entdeckt
werden und mittels Pathologiebefunde gro¨ßenteils (7/8 somatischen Mutationen) besta¨tigt
werden. Lediglich in der Anzahl der identifierten germline Mutationen gab es Unterschiede.
So wurden 36 gefundene germline Mutationen von Mutect2 im ”tumor-only” Modus durch
Wileup nicht identifiziert, da es an diesen Positionen an Genexpression in den RNA-Seq
Daten mangelte. Dafu¨r konnte aber mittels GATK’s Haplotype caller in den Blut-Daten
der Patienten unabha¨ngig besta¨tigt werden, dass es sich um echte germline Mutationen und
nicht um Artefakte handelte. Bei Wileup wurden fu¨nf germline Mutationen identifiziert,
die nicht im ”tumor-only” Modus von Mutect2 entdeckt wurden, da in den Exome-Seq
Daten an diesen Stellen zu hohe Duplikationsraten vorlagen und eine Detektion nicht mo¨glich
war. GATK’s Haplotype caller konnte auch diese Mutationen im Exome-Seq des Blutes der
Patienten nachweisen und besta¨tigen.
Abschließend la¨sst sich sagen, dass die hier pra¨sentierten Publikationen zum immernoch stark
aktuellem Thema der Pipeline Standardisierung im Feld der ”Transciptomics”, speziell der
differenziellen Genexpressionsanalyse, positiv beitragen konnten. Weiterhin war es mo¨glich
die Fragen der Mutationsdetektion in RNA-Seq Daten erfolgreich zu kla¨ren. Außerdem
war es mo¨glich beide Teile meiner anfa¨nglichen Fragestellung in dieser Arbeit erfolgreich an
Echtdaten erproben zu du¨rfen und somit ihre Validita¨t zu besta¨tigen.
2 Introduction
2.1 Motivation of this thesis
Within the last ten years of Next-Generation Sequencing (NGS) and specially RNA-Seq as
become a lot more affordable (Wang et al., 2009). They are overtaking, step by step, the
place of microarray analysis at the topic of unravelling mechanisms of gene expression. The
main reasons for this are decreasing running costs, a higher dynamic range of expression and
low abundance accuracy of RNA-Seq over microarray (Ozsolak and Milos, 2010). Added to
the versatility of RNA-Seq a further factor for the increasing popularity is the possibility of
detecting mutation not only on data derived from DNA sequencing (DNA-Seq), but using
RNA-Seq data.
The precision of current methods for detecting mutations in RNA-Seq is not on par with
state of the art DNA-Seq based methods (McKenna et al., 2010; Cibulskis et al., 2013; Xu,
2018), because of higher alignment error rates near splice junctions, RNA editing and failure
of detecting mutations in gene regions of very low or no expression. Nevertheless, current
methods can provide additional information, like a high expression of low-frequency variants
which are hard to detect in genomic DNA. An additional benefit is the detection of possible
mutation states next to standard differential expression analysis (see 2.3.1.4) and gene set
enrichment analysis (see 2.3.1.5), for no additional financial and biological costs (Goya et al.,
2010; Quinn et al., 2013; Tang et al., 2014). For example, these mutations can not only be
associated to tumour types based on mutation patterns but also it is feasible without the
need of high investments for acquiring new biological samples or redoing the experiment with
DNA based mutation analysis.
This work aims to reveal the best suitable bioinformatical methods to use for standard
analysis of RNA-Seq data and apply them to multiple RNA-Seq data sets. This comprises
the comparison of microarray platforms to several RNA-Seq workflows, evaluation of their
performance and a recommendation for the best performing workflow RNA-Seq data (see
3.1). Afterwards, the workflow is applied in another publication dealing with Colorectal
cancer (CRC) in mice (see 3.3). This dissertation also includes methodological work of a
software for the detection of mutations in RNA-Seq. It is called Wileup, and it can be
applied either on a complete transcriptome or using it on a small panel of mutations with
specific clinical implication on possible drug response (see 3.2). Further, this work evaluates
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the performance of Wileup compared to state of the art analysis tools as a further addition
to standard analysis workflows for RNA-Seq data.
2.2 High-throughput sequencing data
The basic information flow in a cell goes from desoxyribonucleic acid (DNA) to ribonucleic
acid (RNA) (transcribed into messenger ribonucleic acid (mRNA)) and is then translated
into proteins at the ribosome (Crick, 1970). These different cellular contents can also be
described in the context of high-throughput sequencing data, as different subpopulations,
using the term -omics (Greenbaum, 2001). Three of these -omic terms play an important
role in this dissertation: the genome, the exome, and the transcriptome. The complete
DNA, including genes, coding and non-coding nucleotide sequences, are described as the
genome. The exome is a subset of the genome and only describes the regions in the genome,
that are mainly transcribed into mRNA and therefore are protein-coding. According to Ng
et al. (2009), protein coding regions are only representing 1% of the human genome. The
exome defines the transcriptome, but only the transcribed parts at the time point of RNA
measurement for the cellular condition. So it reflects the information of the expressed genes
at that time point, which can vary through cell types and over time.
Of these three -omic data types, transcriptomic and exomic sequencing data were used in
this work to first decide on the best fitting bioinformatical methods at hand and second to
evaluate the performance of detecting mutations based on transcriptomic data using Wileup
instead of the general approach in using exomic data for mutation calling.
2.2.1 Transcriptome profiling
The main challenge with transcriptome profiling is the identification of genes differentially
expressed between two conditions. First, the tools at hand to identify a single molecule
or small amounts of them were Northern blots (Alwine et al., 1977), reverse transcription
polymerase chain reaction (RT-PCR) (Shaffer et al., 1990), expressed sequence tags (ESTs)
(Adams et al., 1991; Nagaraj et al., 2006) and serial analysis of gene expression (SAGE)
(Velculescu et al., 1995). Big advancements in analysing transcriptome data were made with
the development of microarrays first reported in the Science journal in 1995 (Schena et al.,
1995). With these chips, it became possible to analyse the expression of thousands of genes
in parallel on one chip.
Agilent and Affymetrix are two of the main microarray platforms (and are analysed within
the first publication, see 3.1). They differ slightly in their hybridisation techniques of the
RNA and follow-up bioinformatical analysis steps, see Tan et al. (2003) for a thorough
evaluation of commercial microarray platforms.
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Figure 2.1. The generalized processing work flow of microarrays, as exemplified by input tissue samples
and output processed text files. Adapted from Figure 1 in Malone and Oliver (2011).
The main idea behind microarrays is the use of short oligonucleotide probes made of
genomic DNA; a general processing workflow is shown in Figure 2.1. These so-called probes
are complementary to thousands of possible transcripts of interest. They are immobilised on
a solid substrate. The transcripts are extracted from cells or tissues of interest and labelled
with fluorescent dye(s), hybridised to the array, washed and scanned with a laser. Transcript
and their complementary probe counterpart hybridise, and due to the dye(s) at the labelled
transcript, light intensities are detected as a measure of gene expression. Even through
microarrays have good stable analytical solutions and established quality control standards
(Shi et al., 2006, 2010), a new standard for transcript analysis revolutionizedRNA analysis:
RNA-Seq. It introduced several profiling opportunities that microarrays cannot provide.
Because RNA-Seq is direct utilising fragments of transcriptomic sequences, investigations
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of junctions between exons without prior knowledge of a gene model, RNA editing events,
knowledge of polymorphisms, which can support emerging allele-specific expression, are
possible. In contrast, microarray probes are designed by prior genomic sequence data, and
light intensities are used as a surrogate of gene expression. Thus, microarrays will miss
all these differences in gene expression without undergoing great efforts (Kapranov et al.,
2007; Agarwal et al., 2010). Another big advantage of RNA-Seq is the possibility to analyse
non-model organisms for quantification of individual transcript isoforms or alternative splicing
events where the complete genome is not present, and therefore no complementary probes
could be designed for microarrays due to missing annotation (Trapnell et al., 2010; Richard
et al., 2010).
Over the years multiple companies started selling RNA-Seq platforms: Sanger, the first-
generation (Metzker, 2005; Hutchison, 2007), sequencing, Roche/454, Illumina/Solexa,
Life/APG (Zhou et al., 2010) for the next-generation sequencing platforms and Helicos
BioSciences and nanopore (Branton et al., 2008) for the emerging third generation sequencing
platforms. The following explanation of mRNA sequencing will focus on the Illumina’s
platform sequence by synthesis technique, as it is the main platform of all sequencing data
presented in this dissertation. For a full review see Metzker (2010). The protocol for mRNA
sequencing is described in Figure 2.2. First, the samples of interest are getting fragmented,
for example by hydrolysis, and then reverse-transcribed (RT) to make double-stranded
complementary desoxyribonucleic acid (cDNA) utilising random hexamer primers from Illu-
mina. Next, the double-stranded fragments are ligated to adapters at the ends. Afterwards,
they are amplified by Polymerase Chain Reaction (PCR) and injected into a flow cell. The
flow cell is used as a solid phase and consists of a lot of oligonucleotides complementary to
the adaptors ligated to the transcripts.
After the adaptors on the DNA fragments have been hybridised to the complementary
oligonucleotides in the flow cell, the fragments are bridge amplified to generate significant
clusters of clones to be better detected by laser, later on. Then wash and go cycles take
place, where sequencing reagents are added, and in each cycle precisely one nucleotide can
be added to the complementary oligonucleotide for all clusters simultaneously for millions
of clusters on the flow cell. After hybridisation took place, all none added nucleotides are
washed away. Finally, a laser detects hybridised nucleotides. These cycles proceed as long as
the sequenced fragments should be. In this dissertation for instance, the regular nucleotide
length of the fragments for RNA-Seq, so-called reads, were 50 bases long; therefore 50 cycles
took place.
2.2.2 Exome profiling
Typical application, when profiling an exome are the detection of Single Nucleotide Poly-
morphism (SNP) genotyping and the detection of small DNA insertions or deletions (indels)
but also copy number variations (CNVs), rearrangements and inversions of sequences can be
of high interest. SNP are sequence alternatives, so-called alleles, at single base pairs (bp)
positions in the genome. A single bp mutation has to be present in at least 1% of a population
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Figure 2.2. The generalized processing workflow of RNA-Seq based on the Illumnia platform, as example
inputting tissue samples and outputting processed text files. Adapted from Figure 2 in Malone and Oliver
(2011).
to be called a SNP (Brookes, 1999). Therefore the correct naming of mutations, where it
is not known, if at least 1% of the population has it, is Single Nucleotide Variation (SNV),
but are often intermixed. SNVs and SNPs are of special interest, as they are associated
with heritable phenotypes, multifactorial diseases, cancer, drug responses to cancer (Gray
et al., 2000) or most prominent in Mendelian diseases (Ng et al., 2010). The most common
used method to identify SNPs is Whole Genome Sequencing (WGS) and Whole Exome
Sequencing (WES) (Belkadi et al., 2015) but is also well described for microarrays (Kwok
and Chen, 2003). RNA-Seq as a method to identify SNPs (Quinn et al., 2013; Cirulli et al.,
2010) has become a valuable addition, which should not be overseen and is the focus in this
dissertation at publication 3.2.
SNP genotyping with microarrays and DNA-Seq on DNA samples is similar to the described
instruction from Figure 2.1 and 2.2 with the difference, that the starting material is DNA
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instead of RNA and used chemicals have to be adapted for it. There are microarray-based
methods for SNP genotyping from Affymetrix as well as from Illumina, which are successful
and still used. Today SNP arrays are capable of detecting more than one million different
human SNPs. The fraction of SNPs on the array that can be reliably called exceeds 99.5%
according to Bumgarner (2013). Nevertheless, the analysis focus remains on exomic data
based on Exome-Seq from Illumina machines.
2.3 Analysis of Sequencing data
With the new possibilities of data creation, there is a rising need for new methods and
software to manage all the ”-omics” data. This part will consist of an overview of current
bioinformatical tools for dealing with RNA-Seq and Exome-Seq data in a workflow-like
structure of subsections. It will only touch the microarray analysis for transcriptomic data
shortly, as it is mentioned in the publication in section 3.1 and of minor importance nowadays
for the analysis of transcriptomic data.
A crucial prerequisite for a successfully RNA-Seq study is a good experimental design involving
library type, sequencing depth and numbers of replicates dependent on the biological system
under study. Knowledgeable execution of the sequencing experiment itself ensures that data
acquisition does not become undermined by unnecessary biases (Auer and Doerge, 2010).
This statement holds true for Exome-Seq based experiments as well.
2.3.1 Transcriptomic Analysis
The possibilities of analysing RNA-Seq data are as versatile as there are applications of
this technology (Williams et al., 2017). This section addresses the major analysis steps for
differential gene expression followed by interpretations of the differentially expressed genes
via functional profiling. The main steps for a typical transcriptomic analysis are quality
control of the raw input data (see 2.3.1.1), read alignment against a reference genome (see
2.3.1.2), obtaining metrics for gene and transcript expression, so-called counts (see 2.3.1.3),
and detection of differential gene expression (see 2.3.1.4) followed by functional enrichment of
genes into groups (like over-representation of genes in pathways or functional gene-ontology
terms (?)) (see 2.3.1.5). For microarrays, the steps are preprocessing of the raw intensity
values from the chip, normalisation of raw intensities followed by differential gene expression
analysis with optional functional enrichment of significant genes (using Limma (Ritchie et al.,
2015)). There are also different analysis options for applications on RNA-Seq data involving
alternative splicing, identification of fusion transcripts, and small RNA expression, which
are not covered here. For a survey of possible analysis strategies on RNA-Seq data and
accompanying tools see Conesa et al. (2016). An illustration of the most relevant tools for
this dissertation are shown in Figure 2.3.
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Figure 2.3. The workflow for microarray and RNA-Seq analysis structured with the different processing
steps with a selection of tools commonly used in the bioinformatical community surrounded by light blue
bubbles.
2.3.1.1 Quality Control of raw reads
Raw reads are stored in text files. They are called FASTQ files and are a widely accepted and
standardised file format. Each entry of a read in a FASTQ file consists of four lines: sequence
identifier, sequence, quality score identifier line and Phred-scaled base quality scores. Quality
control of raw reads involves the analysis of sequence quality, GC content, the presence of
adaptors, overrepresented k-mers, duplicated reads, and PCR artefacts or contaminations to
evaluate the technical quality of the samples. The range of acceptable k-mer or GC content
levels are dependent on experiment and organisms and should always be checked individually
on each experimental setup. FastQC (Andrews, 2010) is a prominent tool to quality check
Illumina reads, whereas MultiQC (Ewels et al., 2016) is perfect to combine sample based
results into one big overview file from multiple tools across many samples for different steps
during the analysis, not only when doing quality control of raw reads. Software tools like
the FASTX-Toolkit (Hannon, 2009) and Trimmomatic (Bolger et al., 2014) can be used to
trim (discard) low-quality reads, trim adaptor sequences, and eliminate poor-quality bases.
Discarding parts of reads with lousy quality prevents aligning reads to wrong positions
against the reference and therefore erroneously altering the read count in regions where the
reads misalign due to detection errors in the nucleotide sequence during sequencing.
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2.3.1.2 Alignment of reads
Reads are typically mapped to either a genome or transcriptome directly. Each of them
has advantages and disadvantages. Prerequisite for mapping against the transcriptome is a
highly annotated genome to extract the regions with coding sequences, therefore alignments
against a transcriptome are computational quicker.
A good quality check for alignment accuracy is the percentage of mapped reads. Diverging
percentage from 80 % and higher up to nearly 100% total matched reads are observable
for alignments against the genome of well-studied species like mouse and human (Engstro¨m
et al., 2013). Around 55% or more for (see results in publication 3.1) mapping against the
transcriptome. As the transcriptome is only a small part of the genome and alignment rates
go down as a consequence. This is due to the fact that a percentage of the reads cannot
find a matching counterpart to the referenced transcriptome and stay unmapped. On the
contrary, this means that reads also map to noncoding regions when mapped against the
genome, which are not part of the annotated transcriptome. In turn, this could lead to de
novo findings of transcripts or simple stay unannotated for the time being. Reads can map to
only one position at the reference (uniquely mapped) or to multiple positions (multi-mapped
reads). Genomic multi-mapped reads mostly come from repetitive sequences or shared
domains of paralogous genes. They contain valuable information for further downstream
analysis and should not be discarded. When the reference is a transcriptome, multi-mapping
occurs a lot more because a read that would have been uniquely mapped on the genome
would map equally well to all transcripts of a gene in the transcriptome that share the same
exon. Nowadays the decision to map against genome is quite clear, as it allows to identify
novel splice sites and isoforms and does not force reads into the predefined borders of the
transcriptome when they arise from somewhere else in the unannotated genome. At the
beginning of RNA-Seq analysis mapping against the transcriptome was the first thing to
do, as it circumvented the problem to deal with splice junction and reads spanning them
over multiple exons. It was easy to directly apply genomic aligner (bwa (Li and Durbin,
2009), Bowtie (Langmead et al., 2009),) to the transcriptome. Today the problem is solved
and good and fast splice aware aligners are available (STAR (Dobin et al., 2013), TopHat(2)
(Kim et al., 2013) and his successor HISAT2 (Kim et al., 2015), GSNAP (Wu and Nacu,
2010), MapSplice (Wang et al., 2010) and PALMapper (Jean et al., 2010)).
In general, parameters of alignment tools can be tweaked according to the mapping against the
foward or reversed strand, the number of mismatches, the length and type of reads (single-end
or paired-end) and the length of sequenced fragments the reads are derived from. Single-end
reads are reads derive from only one side of a fragment during the library preparation step
before sequencing. Whereas, paired-end reads are derived from both ends of a fragment
and therefore contain distance information between that pair that should not change when
aligned, which can be used to gain knowledge about sequence alterations from the reference.
Besides, existing gene models annotation files can be provided to some aligners to map
exon coordinates accurately and help in identifying splice sites. The addition of gene model
annotation can have a crucial effect (Zhao and Zhang, 2015) on the quantification (see 2.3.1.3)
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of reads towards the gene model (reflected as counts for a gene) and differential expression
analysis (see 2.3.1.4). For a well rounded and comprehensive comparison of RNA-Seq mapper
see Engstro¨m et al. (2013). Worth noting are pseudo aligners like Sailfish (Patro et al., 2014)
its successor Salmon (Patro et al., 2017) and especially Kallisto (Bray et al., 2016), which are
incredibly fast in performing the (pseudo-)alignment and read quantification (see 2.3.1.3) on
the fly in a couple of minutes. These methods usually achieve this by building a coloured de
Bruijn graph from all indexed k-mer possibilities of the read input data, which form nodes in
the graph and the coloured paths are possible transcripts found in the transcriptome. The
coloured paths generate k-compatibility classes for each k-mer, which can be interpreted
as sets of potential transcripts. To achieve this, it is a prerequisite to have a high-quality
transcriptome.
2.3.1.3 Transcript quantification
The next step in analysing transcriptomic data is transcript quantification. As noted at
the end of 2.3.1.2, there are algorithms which rely on counting k-mers without the need of
mapping them to a reference; still, the majority of tools for read-counting relies on aligned
reads. The easiest way to count reads is to aggregate only the uniquely mapped reads, done
in HTSeq-count (Anders et al., 2015), featureCounts (Liao et al., 2014) or the –quant option
in STAR. For the quantification on gene-level a Gene Transfer Format (GTF) file, containing
the genome coordinates of exons and genes, is needed.
More advanced algorithms are needed and have been developed for the estimation of transcript-
level expression by tackling the problem of related transcripts sharing most of their reads.
Cuﬄinks (Trapnell et al., 2012) estimates transcript expression from the mapping information
to the genome obtained from mappers such as TopHat using an expectation-maximisation
approach, which estimates transcript abundances within their so-called tuxedo workflow.
It can estimate transcript de novo from the mapping data alone. Further algorithms that
quantify expression from transcriptome mappings are RNA-Seq by Expectation Maximization
(RSEM) (Li and Dewey, 2011), eXpress (Roberts and Pachter, 2013), Sailfish (Patro et al.,
2014), Salmon (Patro et al., 2017) and Kallisto (Bray et al., 2016) among others. These
methods use multi-mapped reads among transcripts as well and output within-sample
normalised values corrected for sequencing. Additionally, the RSEM algorithm uses an
expectation maximisation approach that also returns transcripts per million (TPM) values
which are a more sophisticated way of normalising counts within samples than by Cuﬄinks
reads per kilobase of exon model per million reads (RPKM) values used for removing gene-
length and library-size effects as discussed by Wagner et al. (2012).
2.3.1.4 Differential gene expression analysis
Within sample normalisations like RPKM or TPM fail when used between samples due
to different transcripts/ count distributions (Bullard et al., 2010) or biases, like Illumina’s
random hexamer priming used in their transcriptome sequencing protocols (Hansen et al.,
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2010). Differential gene expression tools have to take between samples effects into account, for
example by modelling the read count distribution as negative binomial distributed and using
generalized linear models (GLM) followed by, for example, likelihood ratio test, test statistics.
EdgeR (Robinson et al., 2010) or DESeq (Anders and Huber, 2010) and its successor DESeq2
(Love et al., 2014) are prominent examples for this. Limma followed by voom, as the successor
of limma, the standard microarray analysis tool, is also applicable for count data and even
allows to account for the correction of inter-gene correlation structures (Law et al., 2014)
before testing for differential gene expression. Cuﬄinks is another option when positional
biases in the coverage of transcripts are a problem.
Another big issue, when doing differential expression analysis, is the occurrence of batch
effects. Sequencing of all samples from one experiment in the same machine run is often
not possible. Usually, samples are collected over time and distributed in sequencing runs.
These effects should be accounted for by minimising them via appropriate experimental
designs at the beginning of project planning, being included in experimental designs as
cofactors afterwards (Auer and Doerge, 2010) or removed by batch correction methods such
as COMBAT (Johnson et al., 2007) or ARSyN (Nueda et al., 2012). These batch correction
methods, although initially developed for microarray data, are still applicable for RNA-Seq.
At the end of DEA a list of differentially expressed genes (DEGs) between conditions emitted
with statistical annotations, like log2 foldchange, p-value and adjusted p-values.
2.3.1.5 Functionial profiling
Functional annotation of differentially expressed genes is the last step for a standard tran-
scriptomic analysis. It can be divided into two main approaches 1) check for DEGs if
they are enriched in functional annotations, and 2) gene set enrichment analysis (GSEA),
which is based on ranking the expressed genes from the differential expression analysis
for enrichment of genes belonging to a common group or pathway. GSEA was initially
developed for microarrays. RNA-Seq data biases such as gene length have to be accounted
for and RNA-Seq specific tools have been developed. ClusterProfiler (Yu et al., 2012) can
be applied on Gene Ontology terms (GO-Terms) and KEGG pathways and topGO (Alexa
and Rahnenfuhrer, 2010) provides multiple algorithms to deal with the inherent correlation
structure of ontologies, GOstat (Beissbarth and Speed, 2004; Beissbarth, 2006) is a program
which automatically obtains the GO annotations from a database and generates statistics of
overrepresented annotation from the analysed list of genes. ClusterProfiler and topGO are
available via Bioconductor (https://www.bioconductor.org/) for the programming language
R (R Core Team, 2013) and GOstat at http://gostat.wehi.edu.au/.
Functional annotation of not annotated species is possible as well by performing orthology
searches via BLAST (Altschul et al., 1990) analysis based on similarity on sequence or protein
databases like UniProt (Bateman et al., 2017), SwissProt (Bairoch and Apweiler, 1998) or
Pfam (Finn et al., 2016). A handy workflow tool, written in Perl for performing these tasks
is Annocript available at GitHub (https://github.com/frankMusacchia/Annocript).
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2.3.2 Whole Exome Sequencing Analysis
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Figure 2.4. The workflow for somatic Variation Calling structured with the different processing steps
(grey boxes) with a selection of tools commonly used in the bioinformatical community (blue boxes).
Performing a Whole Exome Sequencing Analysis (WESA) has been proven to be a successful
alternative to WGS in detecting SNV genotypes and indels for a fraction of the sequence
needed and therefore correlated with a fraction of the costs (Ng et al., 2010). Variants have
been described to have a more likely neutral or weak effects on phenotypes in non-coding
regions, even in well conserved non-coding sequences (Chen et al., 2007; Kryukov et al., 2005).
Therefore the WESA is suitable to find high impacting variants enriched in a well-selected
subset of the genome.
Another typical use case of WESA is the detection of somatic, here referring to the cell
specific variations, which are likely to have a higher frequency of occurrence in cancer tissue
samples. To differentiate mutations which are germline from mutations which a somatic,
samples are sequenced in pairs. The healthy control sample can be extracted from blood
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(or other non-cancer tissues) to detect germline mutations. The second pair is the sample
coming from the tumour tissue. With these matched samples for one patient, it is possible
to identify a tumour-specific somatic mutation, for the simple reason that the variation does
not occur in the blood sample it is likely to be unique from the tumour. The main steps for
a general WESA are quality control of the raw reads, alignment of reads, post-alignment
processing, variant calling and variant annotation. An exhaustive review of various somatic
mutation callers with descriptions of their underlying algorithms is given by Xu (2018). An
illustration of the workflow for WESA with the most relevant tools for this dissertation is
accompanied again in Figure 2.4.
2.3.2.1 Quality Control of raw reads
Raws reads for Exome-Seq analysis are stored in the same FASTQ file format as stated in
section 2.3.1.1 and equal quality control measures can be applied for them. Minor differences
to transcriptomic reads quality control exist, nevertheless. As the focus in Exome-Seq is
more on single base resolution and detection of indels or complete CNVs it is a lot more
urgent to be strict on selecting qualitative bases of reads and trim more aggressively lousy
quality parts of reads. This has to be counteracted by increased the overall length of reads
during sequencing via increasing the number of sequencing cycles and by sequencing both
ends of a fragment to generate so-called paired-end reads. They shared the same fragment
length distribution and based on this information, conclusions on events like indels as well as
CNVs can be drawn (Bao et al., 2014). In other words, instead of using information on 50
base-pair long reads for mapping as it is often done for transcriptomic analysis, paired-end
reads with at least 100 base pairs are suggested for WESA (as it has been done in the second
publication of this dissertation at 3.2).
2.3.2.2 Alignment of reads
As the reads come from DNA and not from mRNA (with already spliced transcripts), the
reads do not have to span splice junction and alignments become easier than for RNA-Seq
splice aware aligners. Typical genome aligners are BWA (Li and Durbin, 2009), bowtie
2 (Langmead and Salzberg, 2012), segemehl (Hoffmann et al., 2009), which are based on
the Burrows-Wheeler Transformation (BWT) (Burrows and Wheeler, 1994) or on hashing
methods, like Eland (AJ Cox, Illumina, San Diego), ZOOM (Lin et al., 2008), SOAP2 (Li
et al., 2009b), MOSAIK (Lee et al., 2014), Novocraft (http://www.novocraft.com) for DNA
indexing and searching. Hash-based methods are stated to outperform BWT based methods
in speed at the cost of memory usage, whereas BWT based methods offer sensitivity at the
cost of flexibility (Lee et al., 2014).
2.3.2.3 Post-alignment processing
After alignment of reads, the post-alignment processing takes place to increase the quality of
downstream variant calling. It consists of read duplicate removal, indel realignment, and base
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quality score recalibration (BQSR). Also, there is not a general best practice in particular for
each combination of methods out there as aligner and variant caller as well as variation and
sequencing depth of the data play a role. Nevertheless, it is advised to be used and should
be checked in each particular case.
Reads are considered duplicates when they have the same mapping coordinates against
the reference. It is not possible to distinguish them from true DNA material or derived
from the PCR amplification step during sequencing (see 2.2.1). For WES analysis, it is
recommended to remove duplicates before variant calling, to reduce bias due to uneven
amplification of DNA fragments (Xu, 2018). Programs such as Picard MarkDuplicates
(http://picard.sourceforge.net) and SAMtools (Li et al., 2009a) can be used to remove
duplicates.
After duplicate reads are removed areas in the genome, that contain indels has to be found
and realigned to improve the overall alignment quality. The main issue here is that each read
is getting aligned independently resulting in alignments with different mismatch positions
with equal alignment score in gapped regions like indels, which lead to possible artificial
mutation calls. Therefore the quality of alignment for this regions can be improved by
doing local realignments considering all reads at once, so-called multiple sequence alignments.
Programs implementing these are for example Dindel (Albers et al., 2011) and GATK’s
(DePristo et al., 2011) Unified Genotyper and the original Mutect (Cibulskis et al., 2013).
Each read has a Phred-scaled quality score attached, generated by the sequencing machine
as the confidence of the called base at each position of the read. However, the scores
generated during sequencing can be biased (Minoche et al., 2011) and need to be corrected,
if possible. Therefore BQSR is recommended to increase the accuracy of confidence scores
before calling variants. For each base of a read alignment, a corrected Phred-scaled quality
score is calculated assuming that all observed differences between the aligned reads and
the reference genome are sequencing errors. Also, it is necessary to exclude known variants
before score recalibration, as they are true genomic variations and should not be considered
as sequencing errors. GATK BaseRecalibrator (McKenna et al., 2010) and the Bioconductor
package ReQON (Cabanski et al., 2012), which uses logistic regression for recalibration of
the base quality scores, are available for this.
2.3.2.4 Variant Calling
When talking about variant detection, it is important to differentiate between germline and
somatic variants. The first is most likely an inherited mutation related to family history and
the second one is only present in tissue-specific cells. Therefore, both play wide-ranging roles
in tumour development and this should be reflected in the selection of tools used. Popular
somatic SNV caller are MuTect2 (Cibulskis et al., 2013), Strelka (Saunders et al., 2012),
SomaticSniper (Larson et al., 2012) and VarScan2 (Koboldt et al., 2012) utilizing paired
tumour-normal samples, whereas popular germline caller include GATK, SAMtools and
FreeBayes (Garrison and Marth, 2012) utilizing variant detection either on multiple samples
or sample-wise.
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2.3.2.5 Variant Annotation
Identifying biological relevant mutations, like disease-causing mutations, from random errors
or polymorphisms is the aim of variant annotation. Attributes, that can be annotated are a
genomic feature, gene symbol, exonic function and amino acid changes. It has been described
that most disease-causing mutations in Mendelian disorders and many disease-predisposing
SNPs throughout the genome are non-synonymous SNVs and indels in the protein-coding
regions (Rabbani et al., 2014). Therefore many public databases for additional information
of variants have been set up. Public databases such as CIVIC (Griffith et al., 2017), ClinVar
(Landrum et al., 2014), COSMIC (Forbes et al., 2008), RegulomeDB (Boyle et al., 2012),
dbSNP (Sherry et al., 1999), PolyPhen (Adzhubei et al., 2010) and HaploReg (Ward and
Kellis, 2012) are a source of additional knowledge when deciding for the pathology of found
mutations. Programs, that perform these annotations are VariantAnnotator from GATK and
SnpEff (Cingolani et al., 2012) equipped with read filters, Variant filtration, and prioritisation.
2.4 Biology of cancer
2.4.1 What is Cancer?
In healthy mammalian cells, embryogenesis, growth, and tumourigenesis require cell prolifera-
tion. During the acquirement of a broader and more profound knowledge of proliferation-state
regulations, growth-factor signal transduction and transcriptional networks necessary to
initiate and maintain cell cycling, it became known that proliferation relies highly on the
metabolic activities of the cell. The cell requires a high amount of nutrition to divide into
daughter cells, which is a metabolic challenge and vulnerable to disruptive influences. The
cellular uptake and metabolism of nutrients, therefore, depends on extracellular signals, like
hormones, cytokines, and growth factors (Hedeskov, 1968; Whetton et al.; Bauer et al., 2005;
Berridge and Tan, 1995). These extracellular signals also drive cell growth, proliferation, and
survival.
When these extracellular stimuli start to malfunction, for example, introduced by muta-
tions in genes in pathways responsible for signal transduction, they can initiate permanent
cell growth leading to cancer. Normally, uncontrolled growth should activate controlled cell
death, called apoptosis regulated by the tumour suppressor p53 to prevent the cell from
replicating. On the other hand, there are oncogenes and proto-oncogenes, if they are altered
by mutations or overexpressed, they can counteract cell death and promote cell proliferation
ultimately leading to rapid growth, cancer (Todd and Wong, 1999; DeBerardinis et al., 2008).
Cancer can be divided into different sub-types based on their origin. Carcinomas, like in
colorectal, lung breast or prostate cancer usually starts from the skin or the tissue surface of
inner organs and form solid tumours. They are the most common type of cancer. Sarcomas,
they start from tissue connecting the body, like fat, muscles, nerves, tendons, joints, blood
vessels, lymph vessels, cartilage, or bone. Leukaemias are cancer originating from the blood.
Healthy blood cells change and grow uncontrollably. They can be divided into four types:
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acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myeloid leukaemia, and
chronic myeloid leukaemia. Lymphomas, are cancer originating in the lymphatic system,
which is a system of connected vessels and glands to help fight infections. There are two
main lymphomas: Hodgkin lymphoma and non-Hodgkin lymphoma (ASCO, 2012).
2.4.2 Cancer Progression and Metastases
A clonal evolutionary model of cancer development was first proposed by Nowell (1976) and
elaborates upon Darwinian models of natural selection and connects cancer as an asexually
reproducing, unicellular, quasi-species (Greaves and Maley, 2012). Its a repeating process of
clonal expansion, genetic diversification due to occurring gene modifications and mutations,
and selection of subclones in heterogeneous cancer, which may influence the growth of an
entire tumour and thereby actively maintain tumour heterogeneity (Heppner and Miller,
1983). The next step in cancer progression is called metastasation.
At an early stage of cancer, the cancerous cells are bound to a primary site within tissue
boundaries. If the cancer cells manage to dislocate from the primary tumour tissue and
penetrate the walls of lymphatic or blood vessel they can circulate through the body. Of
these circulating tumor cells (CTC) only a minor fraction of only 0.01% manages to establish
distant tumours in organs or tissues. These distant tumours are the fittest subpopulation
of the primary tumour as they managed to survive the circulation and the establishment
in the new microenvironment and therefore are a turning point to the worse as the patient
cannot be cured by local therapy anymore (Liotta and Kohn, 2000). Nowadays genes are
known, which initiate tumour progression and metastasation. They can promote cell motility,
epithelial-mesenchymal transition (EMT), extracellular matrix degradation, angiogenesis or
evasion of the immune system. Prominent examples here are Twist1, Snai1 and Snai2 as
aberrantly regulated transcription factors, or modulators of invasion associated pathways
like hepatocyte growth factor (HGF), VEGF and ERK pathways. It is also known that the
suppression of non-coding RNAs (like miR-126 and miR-335 in breast and gastric carcinomas)
promotes metastatic growth (Yang et al., 2011; Feng et al., 2010).
Metastasis suppressor genes, on the other hand, can inhibit metastasis at any step of
the metastatic cascade. To date, some metastasis suppressor genes are known, such as
nonmetastatic gene 23 (NM23), Kangai 1 (KAI1), KISS1, mitogen-activated protein kinase 4
(MKK4), breast cancer metastasis suppressor 1 (BRMS1), Rho GDP dissociation inhibitor
2 (RhoGDI2), cofactor required for Sp1 transcriptional activation subunit 3 (CRSP3) and
Vitamin D3 up-regulated protein 1 (VDUP1) (Martin et al., 2013).
In this dissertation, multiple datasets of different metastatic tissues were used. In all
three publications, metastatic tissue from different patients and animal having CRC was used.
CRC is the third most common type of cancer and the five years survival rate for patients is
roughly 50% (Machii and Saika, 2014), given that half of them develop distant metastasis in
the liver the survival rate goes down further towards approximately 30% (Leporrier et al.,
2006).
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2.4.3 Treatment of Cancer
Treatment options for cancer typically consist of surgery, systemic and radiation therapy or
a combination of them. Treatment for metastasis is different, as the therapeutic window of
opportunity in which to treat a driver mutation, before clonal expansion and divergence occur
(Gerlinger and Swanton, 2010; Galva˜o and Newton, 2005; Shah et al., 2002), can have closed.
Resulting in narrowed therapeutic options as possible drug resistance in the fittest metastatic
subclones could emerge. Therefore, physicians try different combinations of chemotherapy,
radiation and surgery to remove the metastases. Segal et al. (2003) reported that resistance
exercises reduces fatigue and improves quality of life and muscular fitness. Therefore his
form of exercise can be an essential component of supportive care for these patients. Another
therapy option are targeted therapies. They attempt to exploits a tumour’s dependence on
proliferation and survival pathways. However, it has been shown that this only showed high
success rates in a range of solid tumour types and fails in advanced disease cases, explainable
by the tumour heterogeneity via subclone progression of the cancer (Gore and Larkin, 2011;
Diaz et al., 2012).
Therefore the identification of biomarkers that inform about prognosis, or identify low
frequent clonal subgroups of heterogeneous cancer and metastasis which drive the final disease
outcome is the primary challenge sequencing analysis, and bioinformatics should overcome.
2.5 Aim and structure of this work
The global objective of this work is to understand the capabilities of RNA-Seq analysis
methods and their limits. Two specific aims are defined:
• Evaluating different bioinformatical tools on microarray and RNA-Seq (see 3.1), to
establish a quality standard when performing differential gene expression analysis
followed by gene set enrichment with RNA-Seq samples structured as a workflow.
• Develop a method to detect mutations in RNA-Seq data, as the detection of mutations
is an integrated part of gaining knowledge about the cause of cancer and metastasis
next to differential expression analysis. Therefore the performance and limits of this
application in RNA-Seq had to be checked (see 3.2).
The last paper deals with the successful application of the knowledge for the best-performing
tools from the first paper and utilises the complete RNA-Seq analysis workflow in the back-
ground of colorectal cancer metastasising into the liver in mice (see 3.3).
3 Cumulative part of the dissertation
3.1 A comparative study of RNA-Seq and microarray data anal-
ysis on the two examples of rectal-cancer patients and Burkitt
Lymphoma cells
Reference:
Wolff A, Bayerlova M, Gaedcke J, Kube D, Beißbarth T (2018) A comparative study of RNA-
Seq and microarray data analysis on the two examples of rectal-cancer patients and Burkitt
Lymphoma cells. PLoS ONE 13(5): e0197162.https://doi.org/10.1371/journal.pone.0197162
3.1.1 Summary and discussion
This work aimed to establish a quality standard when performing differential gene expression
analysis followed by gene set enrichment with RNA sequencing (RNA-Seq) samples. Different
methods were compared according to their performance during different steps of analysis
based on real datasets for RNA-Seq and microarray. The best performing pipeline for
RNA-Seq analysis was then used as standard for the analysis of all RNA-Seq samples within
the MetastaSys Consortium (for an application on mice see Paper 3.3).
Matched datasets were prepared to reflect the spectrum of possible platforms to derive
datasets for RNA-Seq (see Table 3.1) and microarray analysis. The rectal cancer (RC)
patient dataset consists of patients having a good and a bad prognosis of recurring metastasis.
Initially planned for an equal samples size of five samples in each group, the prognosis of one
patient changed for the worse resulting into a comparison of four versus six patients. The
data is available at GEO under the accession number GSE99897 for RNA-Seq and GSE100109
for microarray. The second data set is from Burkitt Lymphoma cell lines comprising three
replicates of control samples and three replicates of cell line stimulated with B-cell activating
factor (BAFF).
RNA-Seq data was quality checked, aligned, qualities of mapped reads were manually in-
vestigated, reads were counted and tested for differential gene expression. The microarray
data was preprocessed, quantile normalised and differentially expressed genes were detected.
 3 Cumulative part of the dissertation
Finally, GO-term enrichment analysis was performed on the results of all used pipelines (see
Figure 1 from the Manuscript). In total, five pipelines were evaluated P1 to P4 for RNA-Seq
pipelines and on the left side of Figure 1 the microarray analysis pipeline using limma.
Dataset Microarray RNA-Seq samples
BL2 Affymetrix mRNA 3 CTL and 3 BAFF samples
RC Agilent total RNA 4 good prog. and 6 bad prog. patient samples
Table 3.1. Overview of the datasets and platforms that were spotted or sequenced in the publication.
Three aligners were evaluated based on their total mapping rates as the alignments should
recover as much information from the reads as possible by finding the right locations in the
reference genome. The STAR aligner could map the most reads with a total of 98.98 (±
0.05) % of reads for BL2 and 98.49 (± 0.35) % for RC. TopHat2 could map 97.02 (±0.1) %
and 96.73 (±0.4) % respectively with a slightly higher proportion of unique mapped reads
(see 3.2 for full details). Sailfish cannot deal with any multi-mapping at all. The RC dataset
was made of total-RNA and had a higher percentage of non-coding RNA fragments, which
are not annotated in databases yet and therefore cannot be matched by Sailfish.
Next, the normalised count values derived from HTSeq, RSEM, Sailfish, Cuﬄinks and the
normalised intensities from the microarray were compared via correlation analysis using
1− PearsonCorrelationCoefficient as a distance measure for complete linkage clustering.
The average correlation coefficients between the RNA-Seq methods and microarray were
also observed in other studies (Marioni et al. (2008); Bradford et al. (2010)), but a surprise
was the low correlation results of Cuﬄinks which were worse than the technical differences
explainable by the different techniques from microarray and RNA-Seq. It was expected, that
the difference between the two different platforms used is higher than the methodological
within RNA-Seq methods (see Figure 3 from the Manuscript).
Mapping-rates
STAR TopHat2 Sailfish
BL2 RC BL2 RC BL2 RC
unique 78.61 ± 0.55 83.13 ± 1.85 84.25 ± 0.54 85.40 ± 1.62 84.81 ± 0.85 54.44 ± 3.71
multi 20.37 ± 0.52 15.36 ± 1.69 12.78± 0.48 11.32 ± 1.46 0 0
total 98.98 ± 0.05 98.49 ± 0.35 97.02 ±0.1 96.73 ±0.4 84.81 ±0.85 54.44 ± 3.71
Table 3.2. Overview of unique, multi and total mapping rates in percentages for the three aligners STAR,
TopHat2 and Sailfish.
For differential expression analysis (DEA) the overall number of differentially expressed
genes (DEGs) for the RNA-Seq pipelines were much higher than observed for the microarray
analysis. Moreover, the overlaps of DEGs between the pipelines P1-P4 were compared. DEGs
found by at least two other pipelines were named as ’consensus DEGs’ and genes found by
only one pipeline are called ’DEGs unique’. In the absence of the ground truth, this setup
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uses these two measures as an indicator of pipeline performance. Having a high overlap with
other existing pipelines should generally hint towards a more robust method for pipeline
usage. Also, these proportion are only indicators and are by no means actual true-positives
and false-negatives, but more reflecting the general agreement with other compared methods
and the inconsistency or uniqueness of each method.
For DEG evaluations, the microarray results could not be addressed as the experiment had
no DEGs left after multiple test correction in both datasets. Strikingly, P4(Cuff) had the
lowest Consensus DEGs reflected by both datasets (BL2: 45%, RC: 16.88%) and at the same
time, the highest rate of uniquely found DEGs (BL2: 55%, RC: 79.87%). If we take into
account the low correlation results from before, it seems that this pipeline performance is far
worse than the rest of the tested pipelines. On the other hand P1(HTSeq) closely followed
by P2(RSEM) and P3(Sailfish) had a high number of agreeing DEGs resulting in overall
consistent results (Consensus DEGs: BL2: (169-211 genes), RC: (48-51 genes)) between all
three pipelines. Taking the RC dataset as an example, the pipelines differ by their number
of unique DEGs. P1(HTSeq) had only 9 out of 71 DEGs unique. This little number could
be explained by the conservative approach of HTSeq only utilising unique reads for counting.
P2(RSEM) had 28 out of 96 genes unique, most likely due to integrating multi-mapped reads
as well, resulting in more read counts, which support the easier identification of DEGs by
edgeR. Sailfish had 78 out of 146 genes unique, resulting in a rather high percentage of 53%
unique DEGs, which might be due to the kmer exact match approach from sailfish is not
robust enough against sequencing errors and base mutations in genes, resulting in higher
number of misplaced gene counts, ultimately resulting in higher numbers of identified DEGs.
For a complete overview of the number and percentages as well as the individual overlaps,
have a look at Table 3 (https://doi.org/10.1371/journal.pone.0197162.t003) and figure 4
(https://doi.org/10.1371/journal.pone.0197162.g004) from the publication.
The last evaluation of pipeline performance was done with functional enrichment on Gene
Ontology terms (GO-Terms). As the Microarray results did not show significant genes after
multiple test correction, the threshold was lowered here to less than five % p-value. This was
done to check if at least in the gene ranks amongst the top, have interpretable biological
results, despite not being significant. For the BL2 dataset it is known, that analysis involving
BL2 cell lines stimulated with BAFF, GO-Terms related to immune response should show
up (Mackay and Browning, 2002). In the top 20 significantly enriched GO-Terms four
(GO:0060333 interferon-gamma-mediated signalling pathway, GO:0019886 antigen processing
and presentation of exogenous peptide antigen via MHC class II, GO:0050852 T cell receptor
signalling pathway, GO:0031295 T cell costimulation) were identified with this background
in all pipelines P1-P4. In total 13 out of the 20 GO-terms were linked to the immune system
but only found by P1-P3 consistently. Also, four GO-terms are related to metabolism, two
to cell signalling and the last one to biological regulation. For the microarray data, only one
of these GO-term was significant, and seven were not detected at all.
When comparing GO-term analysis results of the rectal cancer patient group, it was expected
to see GO-terms related to metastases formation, like increased proliferation, cell rearrange-
ments, changes in cell organisation and to a specific extent immune response as well. Therefore
 3 Cumulative part of the dissertation
it was checked again if several of these assumptions within the top 20 significantly enriched
GO-terms could be observed. From these, GO-terms (GO:0090263, GO:0002158, GO:0090090)
linked to cellular proliferation, GO-terms (GO:0030199, GO:0022617, GO:0071711) linked
to cellular rearrangements and GO-terms (GO:0060337, GO:2000551, GO:0030853) related
to immune system response could be identified. However, a lot of significant GO-terms
could not be related to any of the expected cellular response classes. The full setup
of each of the 20 GO-Terms for both datasets is present in the publication at figure 5
(https://doi.org/10.1371/journal.pone.0197162.g005)
In conclusion, the combination of STAR aligner with HTSeq-Count followed by STAR
aligner with RSEM and Sailfish generated differentially expressed genes best suited for the
dataset at hand and in agreement with most of the other transcriptomic pipelines. As
RSEM is utilising multi-mapped in addition to unique mapped counts for isoform and gene
expression, the final pipeline for MetastaSys consisted of STAR for alignments, RSEM for
read counting followed by edgeR for DEA and topGO for functional level annotation of gene
ontologies. If your interest is not in high variable cancer data and no high-performance
cluster for analysis is available, Sailfish is a good option to do the CPU and memory intense
alignment and counting part, resulting in a reliable and profound analysis suitable for a
typical desktop setup.
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Abstract
Background
Pipeline comparisons for gene expression data are highly valuable for applied real data
analyses, as they enable the selection of suitable analysis strategies for the dataset at hand.
Such pipelines for RNA-Seq data should include mapping of reads, counting and differential
gene expression analysis or preprocessing, normalization and differential gene expression
in case of microarray analysis, in order to give a global insight into pipeline performances.
Methods
Four commonly used RNA-Seq pipelines (STAR/HTSeq-Count/edgeR, STAR/RSEM/
edgeR, Sailfish/edgeR, TopHat2/Cufflinks/CuffDiff)) were investigated on multiple levels
(alignment and counting) and cross-compared with the microarray counterpart on the level
of gene expression and gene ontology enrichment. For these comparisons we generated
two matched microarray and RNA-Seq datasets: Burkitt Lymphoma cell line data and rectal
cancer patient data.
Results
The overall mapping rate of STAR was 98.98% for the cell line dataset and 98.49% for the
patient dataset. Tophat’s overall mapping rate was 97.02% and 96.73%, respectively, while
Sailfish had only an overall mapping rate of 84.81% and 54.44%. The correlation of gene
expression in microarray and RNA-Seq data was moderately worse for the patient dataset
(ρ = 0.67–0.69) than for the cell line dataset (ρ = 0.87–0.88). An exception were the correla-
tion results of Cufflinks, which were substantially lower (ρ = 0.21–0.29 and 0.34–0.53). For
both datasets we identified very low numbers of differentially expressed genes using the
microarray platform. For RNA-Seq we checked the agreement of differentially expressed
genes identified in the different pipelines and of GO-term enrichment results.
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Conclusion
In conclusion the combination of STAR aligner with HTSeq-Count followed by STAR aligner
with RSEM and Sailfish generated differentially expressed genes best suited for the dataset
at hand and in agreement with most of the other transcriptomics pipelines.
Introduction
Transcriptomics as an area in the research field of functional genomics has always been a key
player for identifying interactions and regulations of gene expression. Over the last two
decades it was common practice to use microarrays for any investigation in transcriptomics.
Within the last ten years the next generation sequencing (NGS) and especially RNA sequenc-
ing (RNA-Seq), became widely available [1]. These technologies are gradually replacing micro-
arrays, when analyzing and identifying complex mechanism in gene expression. Decreasing
running costs, higher dynamic range of expression and higher accuracy in low abundance
measurements [2] are the main factors for this fast development of NGS and increasing use of
RNA-Seq over microarray.
The versatility in using RNA-Seq, like discovering novel small RNAs (smRNA), microRNA
(miRNA), long-non-coding RNAs (lncRNA) or alternative splicing events [3], is a further fac-
tor for an increasing popularity of this profiling approach. Another advantage is the currently
highly discussed variant calling [4] [5] [6] based on RNA-Seq data, which makes this technol-
ogy even more attractive. The developments of new technologies, like Pacific Bioscience or
Nanopore [7], can further contribute in the field of RNA-Seq and transcriptomics in form of
more detailed annotation databases in the future.
A typical application for RNA-Seq is the differential gene expression analysis. First, millions
of short reads are produced, which are mapped to a reference genome. Subsequently, the
amount of reads mapping to a genomic feature of interest (for example a gene, transcript or
exon) is measured as the abundance of these features [8]. The abundance per feature is used as
an input for differential expression analysis.
Still, microarrays are widely used because of their lower costs compared to the RNA-Seq
technology. Moreover, there are large and well maintained repositories, such as ArrayExpress
[9] and Gene Expression Omnibus (GEO) [10], that have collected the microarray data over
long time periods. RNA-Seq data collections are increasing in GEO and the The Cancer
Genome Atlas (TCGA, https://cancergenome.nih.gov/).
While the preprocessing and analysis steps of microarray data are mostly standardized, the
establishment of RNA-Seq data analysis methodology and standards is still ongoing in the
field of transcriptomics. A lot of efforts have been performed into method comparison studies
to change this [11] [12] [13] [14]. The quality evaluation of different RNA-Seq (pre-)process-
ing methods are one important step to establish a quality standard. Great effort in this field
have been accomplished, for instance by Sequencing Quality Control (SEQC) consortium [11]
and has already been done for microarrays years ago in the MAQC-I and MAQC-II projects
[15] [16].
We aim to investigate commonly used RNA-Seq pipelines on multiple levels (alignment,
counting) and cross-compare the results with the microarray counterpart on the level of gene
expression and gene ontology enrichment. For these evaluations we generated two matched
microarray and RNA-Seq datasets: rectal cancer (RC) patient data (good versus bad prognosis
patients) and Burkitt Lymphoma (BL2) cell line data (control versus stimulated cells).
A comparative study of RNA-Seq and microarray data analysis on two examples
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Materials and methods
Burkitt Lymphoma cell-line data (BL2)
BL2 cells were cultivated as described previously at cell densities between 2 × 105 and 1 × 106
cells/ml [17]. For stimulation studies, cells were cultured in cell culture medium supplemented
with 10 mM HEPES at 1 × 106 cells/ml and incubated with B-cell activating factor (BAFF) for
up to 24 hrs instead of 9hrs [18]. RNA was isolated with RNAeasy Plus Mini Kit (Qiagen)
according to the manufacturer’s instructions and labeled using Affymetrix GeneChip IVT
Labelling Kit (Affymetrix). Fragmentation and hybridization on Human ST1.0 Arrays were
processed according to manufacturer’s recommendations by the TAL (UMG, Germany).
Microarray based profiling was performed using Affymetrix GeneChip Human Gene 1.0 ST
array in three independent replicates of the experiment with the stimulated versus unstimu-
lated cell line. For RNA-Seq, single-end sequencing on an Illumina HiSeq 2000 machine with
the poly-A capturing protocol with 43 base pairs read length was used. The RNA was isolated
using Trizol reagent including a DNase I (Roche, Mannheim, Germany) digestion step and
Library preparation was performed using the TruSeq Stranded Sample Preparation Kit (Illu-
mina, RS-122-2201) starting from 1000 ng of total RNA. Accurate quantitation of cDNA
libraries was performed using the QuantiFluor TM dsDNA System (Promega). The size range
of nal cDNA libraries was determined applying the SS-NGS-Fragment 1–6000 bp Kit on the
Fragment Analyzer from Advanced Analytical (320 bp). cDNA libraries were amplified and
sequenced by using the cBot and the HiSeq2000 from Illumina. The BL2 dataset is accessible
through GEO Series accession number GSE99768 for the RNA-Seq dataset and GSE100112 for
the microarray data.
Rectal cancer patient data (RC)
The rectal cancer patient dataset consists of 10 patients from a clinical study at the Surgery
department of the University Medical Center Go¨ttingen collected over a longer time. Patients
were chosen based on the follow-up time and development of a distant metastasis. First a bal-
anced sample size of five versus five patients with and without a metastatic event was intended.
A later development of metastasis of one of the good prognosis patients changed the sample
size to 6 versus 4 patients. The study is approved from the Ethic commission of the University
medical centre Go¨ttingen, ethic number: 9/8/08. Biopsies were immediately stored in RNAla-
ter (Qiagen, Hilden, Germany). Subsequently, for microarray RNA was isolated using TRIzol
(Invitrogen, Carlsbad, CA) according to the manufacturer´s instructions. Nucleic acid quan-
tity, quality and purity were determined using a spectrophotometer (Nanodrop, Rockland,
DE) and a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). 1 μg of total RNA was
labeled with Cy3 using the Low RNA Input Fluorescent Linear Amplification Kit according to
the manufacturer’s recommendations (Agilent Technologies, Santa Clara, CA). Quantity and
efficiency of the labeled amplified cRNA were determined using the NanoDrop ND-1000
UV-VIS Spectrophotometer version 3.2.1. 1.5 mg of Cy3-labeled cDNA was hybridized to an
oligonucleotide-based Whole Human Genome Microarray (4x44K, Agilent Technologies) and
incubated at 65˚C for 17 hours. Slides were washed and scanned using an Agilent G2565BA
scanner.
For RNA-Seq single-end sequencing for 50 base pair reads the RNA was isolated using Tri-
zol reagent including a DNase I (Roche, Mannheim, Germany) digestion step. Library prepa-
ration for RNA-Seq was performed using the TruSeq Stranded Sample Preparation Kit
(Illumina, RS-122-2201) starting from 1000 ng of total RNA. Accurate quantitation of cDNA
libraries was performed using the QuantiFluor TM dsDNA System (Promega). The size range
A comparative study of RNA-Seq and microarray data analysis on two examples
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of nal cDNA libraries was determined applying the SS-NGS-Fragment 1–6000 bp Kit on the
Fragment Analyzer from Advanced Analytical (320 bp). cDNA libraries were amplified and
sequenced by using the cBot and the HiSeq2000 from Illumina for single end reads with a base
pair length of 50.
The RC dataset is accessible through GEO Series accession number GSE99897 for the
RNA-Seq dataset and GSE100110 for the microarray data.
Microarray data preprocessing and analysis
All preprocessing and statistical analyses of microarray data were performed using R statistical
computing environment [19]. Affymetrix BL2 data was processed using the custom CDF file
(hugene10st_Hs_ENTREZG), getting the most complete gene meta data annotation for the affy-
metrix probe ids. Afterwards the Robust Multi-array Average (RMA) algorithm was applied
[20]. Adittional quality control metrics for BL2 can be found in the supplements (S1 File).
Both datasets were log2 transformed and quantile normalized. In case of several probes corre-
sponding to the same Ensembl gene identifier, the probe with median expression intensities
was chosen to represent the gene level expression. Differential expression analysis was per-
formed by fitting linear models using empirical Bayes method as implemented in the limma r-
package [21] and p-values were adjusted for multiple testing using Benjamini-Hochberg (BH)
method [22].
NGS data preprocessing and analysis
NGS quality control. The raw reads from both datasets were quality assessed using fastqc
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Beside an agglomeration of
nucleotides with slightly lower quality at the starting positions than in the middle of reads, no
major quality issues were observed (S1 Table, S1a and S1b Fig). For each samples the distribu-
tion of unique, multi- and unmapped reads were checked for high proportion of unmapped or
multi mapped reads, which were not explainable by the underlying alignment methods (S1
Appendix).
Generation of alignments. Different state-of-the-art RNA-Seq aligners were compared:
STAR, TopHat2 and Sailfish.
STAR (v2.4.0h) is a splice-aware ultrafast universal RNA-Seq aligner, which utilizes a
sequential maximum mappable seed search in uncompressed suffix arrays followed by seed
clustering and a stitching procedure [23]. TopHat2 (v2.0.13) is as well a splice-aware RNA-Seq
aligner which uses a two-step approach: 1. detecting potential splice sites for introns, 2. using
these candidate splice sites in a subsequent step to correctly align multi exon-spanning reads
[24]. Sailfish (v0.6.3) works differently and is not directly an aligner, since it avoids mapping of
reads entirely and utilizes the observation of k-mers occurring in reads instead of alignments
of reads [25].
Reads obtained from RNA sequencing were mapped against the reference genome of
Homo sapiens Ensembl Version GRCh38.76 utilizing further information from the gene trans-
fer format (.gtf) annotation from Ensembl version GRCh38.76. In case of Sailfish, it required a
precomputed set of transcripts in fasta format. This was done with RSEM’s rsem-prepare-ref-
erence function providing the reference and the .gtf annotation.
Generation of counts. Multiple tools for counting of reads overlapping gene features
were utilized: HTSeq, RSEM, Sailfish, and Cufflinks.
HTSeq-Count is a tool from the Python Toolbox HTSeq (v0.5.4p1) for counting reads over-
lapping into a specific feature (gene) [26]. RSEM (v1.2.19) is a software package for quantifica-
tion of gene and isoform abundance estimation, utilizing an expectation maximization
A comparative study of RNA-Seq and microarray data analysis on two examples
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algorithm [27]. Sailfish an alignment-free tool to estimate isoform abundances via an expecta-
tion maximization algorithm, directly from a set of reference sequences, using k-mers as main
transcript coverage unit. Cufflinks (v2.0.13) performs estimation of abundance with a likeli-
hood based approach for simultaneous estimation of bias parameters and expression levels
[28].
Later comparisons are based on tpm (transcript per million) values. Therefore, after statisti-
cal testing, the fragments per kilobase per million (fpkm) values and normal read count data
were transformed (Supplement S2 Appendix) to tpm values for comparability in figures, using
the R programming language.
Correlation analysis. The correlation analysis were done by taking the mean of each sam-
ple wise correlation test between pipeline methods. As distance measure we took 1-Pearson
correlation, followed by complete linkage hierarchical clustering of the samples. All calculation
were performed in R.
Analysis of differential gene expression. After counting reads, all abundance values were
compared with edgeR, performing a likelihood ratio test (glmLRT). This R-package imple-
ments a range of statistical methods based on the negative binomial distributions, like empiri-
cal Bayes estimation, exact tests, generalized linear models and quasi-likelihood tests [29].
Cufflinks does not deliver read count data and therefore had to be tested by Cufflinks cuffDiff
[30].
As cutoff for significantly differentially expressed genes after multiple testing correction
(BH), a false discovery rate (FDR) of five percent was used. All results after differential gene
expression were transformed into tpm (S2 Appendix) and the significant genes of each Pipe-
line result were used as input for gene ontology enrichment analysis.
Pipelines. Based on the described steps and tools used, 4 different pipelines were set up
(Fig 1) and named as follows: P1(HTSeq) including STAR, HTSeq-Count and edgeR; P2
(RSEM) consisting of STAR, RSEM and edgeR; P3(Sail) with Sailfish and edgeR; P4(Cuff) con-
sisting of TopHat2, Cufflinks and CuffDiff.
Gene ontology enrichment analysis (GO analysis). Genes with an FDR smaller than 5%
where selected and sorted as a gene-list in ascending order. These gene-lists derived from
edgeR, CuffDiff and limma were used as input for the weighted fisher-exact test implemented
in the package TopGO version 1.0 [31] to calculate the enrichment for each GO-category. The
GO-Enrichment analysis tests if a selected feature set (gene-list of DEGs) falls into a Gene
Ontology category more often than expected by chance. GO-terms with a p-value smaller than
5% were considered significant and used subsequently for visualizations.
Results and discussion
The aim of this study was to evaluate common analysis methods for RNA-Seq differential gene
expression and cross-compare them with well established analysis methods for microarray.
The comparisons were evaluated based on matched microarray and RNA-Seq profiles of two
datasets: 1.) rectal cancer patient dataset comprising four patients with a good prognosis and
six patients with a bad prognosis (referred to as RC dataset). 2.) Burkitt Lymphoma cell line
dataset comprising three replicates of control cell line and three replicates of cell line stimu-
lated with BAFF (referred to as BL2 dataset). RNA-Seq data was quality checked, aligned, qual-
ities of mapped reads were manually investigated, reads were counted and analyzed for
differential gene expression. The microarray data was preprocessed, quantile normalized and
differentially expressed genes were detected. Finally a GO-term enrichment analysis was per-
formed on the results of all used pipelines (Fig 1).
A comparative study of RNA-Seq and microarray data analysis on two examples
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We evaluated four RNA-Seq pipelines (P1 –P4) based on different analysis steps: aligning
(section ‘Performance of Alignment tools’), then we cross-compared these pipeline and micro-
array results (MA) based on correlation of expression levels (section ‘Gene-wise correlation of
RNA-Seq and microarray data’), differential gene detection (section ‘Results of differential
gene expression’) and pathway enrichment detection (section ‘GO-Enrichment analysis’).
Performance of alignment tools
The BL2 data was profiled by poly-A-mRNA sequencing whereas RC data by total-RNA
sequencing. For investigating the mapping performance on BL2 and RC, three different align-
ers for read mapping, STAR, TopHat2 and Sailfish, were investigated and the results
compared.
The three aligners were evaluated based on their total mapping rate (see Table 1), where
the aim should be to always map as much data correctly as possible. In the BL2 datasets the
Fig 1. The different analysis pipelines. The flowchart describes the different tools and steps used for microarray (blue) and RNA-Seq analysis (green).
Tasks and tools used at different steps are colored in light blue. Tools corresponding to the same steps are grouped and colored as follows: green (P1
with STAR, HTSeq and EdgeR), blue (P2 with STAR, RSEM and edgeR), red (Sailfish and edgeR) and purple (TopHat2, Cufflinks and CuffDiff).
https://doi.org/10.1371/journal.pone.0197162.g001
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proportion of mapping rate results were close together. For the RC data, aligners that map to
the genome (TopHat2, STAR) performed much better than an aligner mapping to a transcrip-
tome, like Sailfish.
Therefore we took a closer look into the proportions of unique and multi mapping rates,
which together result in the overall mapping rate (Fig 2). STAR showed an overall lower
unique mapping rate (BL2 78.61%, RC 83.13%) than TopHat2 (BL2 84.81%, RC 85.4%), but
got a higher total mapping rate of reads, due to a higher multimapping rate (STAR (BL2
20.37%, RC 15.36%), TopHat2 (BL2 12.78%, RC 11.32%)). For a full list of the complete map-
ping-performance see S1 Appendix. Depending whether or not to use multi mapped reads for
later counting of features, in case of using them STAR performs slightly better than TopHat2.
If only unique mapped reads are utilized, Sailfish performed the best for the BL2 dataset,
which is based on poly-A mRNA sequencing. The performance of Sailfish on the RC dataset is
a lot worse than for STAR or TopHat2. This is due to multiple reasons: as Sailfish is mapping
against known transcripts only, its performance is based on the quality of the species reference
Table 1. Overview of total mapping rates over all samples in % for the different RNA-Seq aligner. Displayed are
the mean mapping rates over the complete dataset with the variance in brackets.
Dataset\Tools STAR TopHat2 Sailfish
BL2 98.98 (±0.05) 97.02 (±0.1) 84.81 (±0.85)
RC 98.49 (±0.35) 96.73 (±0.4) 54.44 (±3.71)
https://doi.org/10.1371/journal.pone.0197162.t001
Fig 2. Mapping distribution. Mapping distribution in % for all three Aligners for both datasets. On the left the BL2 dataset and on the right the
RC dataset is shown.
https://doi.org/10.1371/journal.pone.0197162.g002
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transcriptome. For the BL2 dataset the unique mapping rate is 84.81%, which is better than
STAR’s (78.61%) and TopHat’s unique mapping rate (84.25%). Sailfish allows only for perfect
(unique) matched reads (kmers) and all multi mapped reads are inherently discarded during
the processing by Sailfish. Variant rich data, contradicts the unique matching dogma of Sail-
fish, which could lead to less mapped reads overall. This phenomenon described is illustrated
in the RC data by only 54.44% of mapped reads. The data is based on total-RNA sequencing,
where only around 54% of the dataset is annotated when building the transcriptome, as such a
large proportion of it seems still unknown and therefore cannot be mapped with Sailfish, yet.
Nevertheless, in terms of time required for aligning the data, the performance of Sailfish
was the fastest. As an example: the read mapping for RC took Sailfish 6–7 minutes per dataset
including the counting step, whereas STAR took 6–10 minutes per aligning sample and
TopHat2 up to three hours.
Evaluation of RNA-Seq pipelines and cross-comparison with microarray
Gene-wise correlation of RNA-Seq and microarray data. We performed a gene-wise
correlation analysis based on expression levels after counting. We correlated the different
quantification levels after they were transformed into log2 tpm (RNA-Seq) and log2 quantile
normalized expression values (microarray).
The correlation heatmaps shown in Fig 3 were done by taking the mean of each sample
wise correlation test between pipeline methods. Last, they were clustered based on complete
linkage with the distance 1-Pearson correlation. Overall we observed a high correlation on all
performed RNA-Seq Pipeline runs together with the corresponding microarray values, which
was observed similarly in other studies as well [32] [33] [34] [35] for different datasets. The
correlation of microarray and RNA-Seq data is moderately worse for the RC data (ranges of
0.67 to 0.68) than for the BL2 data (0.87 to 0.88), which can be expected, since the overall bio-
logical variability of patient data is higher than in cell lines. The overall difference in correla-
tion between microarray and RNA-Seq can be explained by their technological difference in
the quantification of the gene expression. For RNA-Seq analysis the Pipeline P4 utilizing Cuf-
flinks and CuffDiff was a big surprise since the mean correlation coefficients where quite
low, even when correlating the replicate of the same method with each other. Microarray
methods measure the intensities of fluorescence, which mirrors the associated gene expression,
whereas RNA-Seq methods measure read counts as associated relative abundance measure for
gene expression levels. Interestingly, the correlation between the different RNA-Seq tools is
high (BL2: 0.97 to 0.99, RC: 0.94 to 0.98). Only a minor impact of mapping and counting
approaches is observed in correlation coefficients. RSEM shows the highest correlation with
the microarray data on both sets closely followed by Sailfish, HTSeq-Count and Cufflinks.
Results of differential gene expression. On the differential gene expression level all pipe-
lines were compared based on the number of significantly differentially expressed genes
(DEGs). P1, P2 and P3 were tested for differential expression with edgeR, P4 with the CuffDiff
script of Cufflinks and limma was used for microarray analysis.
Overall the number of DEGs for the RNA-Seq pipelines were much higher than observed
for the microarray analysis. Moreover, we evaluated overlaps of DEGs between the P1-P4 pipe-
lines. In particular, we focused on the subsets of genes that were detected by at least two out of
four pipelines (’consensus DEGs’) and the subset of genes that were detected solely by only
one pipeline (’DEGs unique’). In the absence of the ‘ground truth’ we use these measures
(‘consensus DEGs’ and ‘unique DEGs’) as indicator of pipeline performance in terms of identi-
fying potential true-positive results and false-positive results. Also these proportion are only
indicators and are by no means actual true-positives and false-negatives, but more reflecting
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the general agreement with the other compared methods and the inconsistency or uniqueness
of each individual method.
Microarray results. For the two investigated datasets we identified very low numbers of
DEGs using the microarray platform. For BL2, out of 1196 genes significant on p-value level
only 1 gene (GPER) remained significant after FDR correction. For the RC dataset, out of 1285
genes significant on p-value level no gene remained significant after FDR correction (S2b Fig).
We checked these genes with the results of differential expression analysis for microarray
reported in Schrader et al. [18], which did a similar study with nearly the same condition. We
could reidentify 26 genes based on the gene symbols in common (see supplement S2 Table). A
reason for this small number of overlapping genes could be attributed to the difference in
power of the analysis and experimental conditions. Our BL2 dataset was newly resequenced,
incubated for 24h instead of 9h and the microarray chip used was the HG-U133_Plus_2 chip
instead of U133 plus 2.0.
Fig 3. Correlation of all samples after analysis. The heatmap describes the combined Pearson correlation coefficient over all pairwise correlation tests
of normalized gene expression against all replicates between groups. For RNA-Seq all expression values are normalized to tpm (transcript per million),
to be able to compare them. Fig. 3A and 3C show the BL2 dataset and the correlation of all samples before (A) and after (C) BAFF stimulation for each
analysis tool used. Fig 2B and 2D show the correlation of patient samples for the two groups with good prognosis of distant free metastases (good) and a
bad prognosis (bad) together with the different analysis pipelines used.
https://doi.org/10.1371/journal.pone.0197162.g003
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RNA-Seq Pipeline comparison on BL2. P1 to P3 found the highest amount of DEGs
(287, 340, 375) after FDR correction. For P4, only 20 genes were left and for the microarray
results one gene was left significant after p-value adjustment (Table 2). 29 of these FDR cor-
rected genes could also be reidentified from a former study from Schrader et al. [18] and are
commonly shared by the pipelines of P1, P2 and P3 (see supplement S2 Table). When adding
P4, the number reduced to 4.
Next, we identified the different overlaps of DEGs for the individual pipelines (P1-4 in Fig 4
BL2). Since we don’t know the true calls for the dataset we utilized ‘consensus DEGs’ and
‘unique DEGs’ as surrogate measures supporting the interpretation of the overlaps.
Considering all four RNA-Seq pipelines a total of 9 genes can be found in common by all
pipelines for BL2. P4(Cuff) pipeline detected 20 DEGs from which 9 were found also by the
other pipelines. These genes are: TSPAN11, PFKFB4, SGK1, CCR7,NFKBIE,CCDC28B,
HLA-DQA1,HLA-DRB5, HLA-DQA2.
For evaluation purposes, we consider the genes found by the majority of tools as promising
candidates for true findings. Therefore, we are looking at the overall agreement between the
tools in form of overlaps of genes in common by at least 2 other pipelines (Table 3) as a mea-
surement of potentially true findings for the tools. It can be seen that P1(HTSeq) has the largest
number of significant genes also found by others (211/287), which is 73.52% of their complete
findings. P1 got the lowest percentage of genes found unique (19.16%), which translates to 55
out of 287 genes. Genes not found by other pipelines can either way be interpreted as false calls
or as simply missed by the other pipelines or most likely a mixture of both. Since finding false
Table 2. Overview of the number genes and GO-terms significant (p-value<5%) and after FDR correction for P1-4 and microarray. The GO-terms for microarray
are in bold, because the p-value was used as a cutoff instead of the FDR.
Pipelines Number of DEGs (p-value) Number of DEGs (FDR) Number of sign. GO Terms
BL2 RC BL2 RC BL2 RC
P1(HTSeq) 2299 3377 287 71 138 127
P2(RSEM) 2329 3646 340 96 131 111
P3(Sail) 2410 1285 375 146 158 127
P4(Cuff) 316 1398 20 154 89 96
Microarray 1196 1289 1 0 116 148
https://doi.org/10.1371/journal.pone.0197162.t002
Fig 4. Significant overlapping genes for the different strategies after multiple test adjustment. Shown are two venn
diagrams, one for each dataset (BL2 Fig. 4A and RC Fig. 4B). The different pipelines used here are: TopHat2 and
Cufflinks (T&C), STAR and HTSeq-Count (S&HT), Sailfish (Sa), STAR and RSEM (S&R). The microarray data is not
included, because there were close to no significant genes after FDR adjustment.
https://doi.org/10.1371/journal.pone.0197162.g004
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calls in general is not desired, we tend to consider a low amount of unique genes found as posi-
tive. Following this interpretation, the quality of the pipelines in their outcome for the BL2
dataset can be ordered as follows: P1(HTSeq), P2(RSEM), P3(Sail), P4(Cuff).
RNA-Seq pipeline comparison on RC. The ordering of the highest amount of significant
genes after FDR correction flipped in this dataset for P1-4. This time P4 found the largest
number of significant genes (154), followed by P3(146), P2(96) and P1(71). P1 has the highest
percentage of consensus DEGs 67.60% (48/71), followed by P2 52.08% (50/96), P3 34.93% (51/
146) and P4 16.88% (26/154) (Table 3). A total of 19 genes (Fig 4 RC) can be found in com-
mon, namely: EYA1, NPR3, MUC5B, RSAD2, IGF2BP3, ITGA11, IFI44L, IFI44, ASZ1, MX1,
CTHRC1, FAM3B, POU5F1B,COL11A1,C1QC, SLC35D3, ZFHX4, MMP11, ANO1. P4 has the
highest number of DEGs, but only 26 of them found by others, whereas a total of 79.87% (123/
154) of the genes cannot be found by any of the other pipelines.
This is highest rate of unique genes found, as well as the lowest rate of Consensus DEGs
consistent in both datasets, despite here having the most genes found. Notably, Cufflinks is
coupled with CuffDiff for the differential expression analysis, so the results of Cufflinks are as
well influenced by differences in the statistical analysis. Overall P4 is the most divergent from
all others, whereas P1 provides the results most concordant with the other pipelines, followed
by P2.
GO-Enrichment analysis. To evaluate the results from BL2 and RC datasets after differ-
ential gene expression analysis enriched GO-terms were investigated. Microarray results
showed close to no significant genes after FDR correction. To nevertheless generate GO-term
enrichment results for microarray based datasets, their significance threshold for the enrich-
ment test was altered to<5% of the p-value instead of<5% FDR value (Table 2). Fig 5 shows
the top 20 significant GO-terms from the different pipelines and microarray datasets. Hierar-
chical clustering of all GO-terms was applied to investigate the similarity of the different pipe-
lines based on the enrichment scores. The complete set of significant pathways is depicted in
S3a Fig for dataset BL2 and in S3b Fig for dataset RC.
BL2 dataset. In the context of comparing control Burkitt Lymphoma cell-line with the
BAFF stimulated BL2 cells, it is to be expected to detect GO-terms related to the immune
response as significantly enriched [36].
We checked whether we find this biological context in the top 20 significantly enriched
GO -terms. In Fig 5A we can observe four highly enriched GO-terms related to immune
response (GO:0060333, GO:0019886, GO:0050852, GO:0031295), primarily for pipelines
P1-P4. In total we see 13 out of the 20 GO-terms linked to the immune system. In addition,
four of the depicted GO-terms are related to metabolism, two to cell signaling and the last one
to biological regulation. The enriched terms based on the microarray data leads to only one
GO-term being highly significant, while 7 were not detected to be significantly enriched at all.
Fig 5a shows that P1 to P3 perform similarly in terms of additional enrichment analysis.
Table 3. Overview of the proportion of genes and corresponding percentage of differential expressed genes for each pipeline after multiple testing adjustment.
‘consensus’ stands for the amount of genes shared with at least two other pipelines and ‘unique’ for genes not found by any other Pipeline from the total amount of genes
found by each Pipeline.
Pipelines Consensus DEGs DEGs unique
BL2 RC BL2 RC
P1(HTSeq) 73.52% (211/287) 67.60% (48/71) 19.16% (55/287) 12.68% (9/71)
P2(RSEM) 49.70% (169/340) 52.08% (50/96) 29.41% (100/340) 29.17% (28/96)
P3(Sail) 52.80% (198/375) 34.93% (51/146) 41.60% (156/375) 53.42% (78/146)
P4(Cuff) 45.00% (9/20) 16.88% (26/154) 55.00% (11/20) 79.87% (123/154)
https://doi.org/10.1371/journal.pone.0197162.t003
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However Pipeline P4 and the microarray datasets show highly different enrichment scores. In
summary, the deregulated GO-terms associated to immune response are identified by the
majority of the pipelines.
RC dataset. When comparing GO-term analysis results of the rectal cancer patient group,
we expect to see GO-terms related to metastases formation, like increased proliferation, cell
rearrangements, changes in cell organization and to a certain extent immune response as well.
Therefore we checked again if we observe several of these assumptions within the top 20 signif-
icantly enriched GO-terms. In these we observed GO-terms (GO:0090263, GO:0002158,
GO:0090090) linked to cellular proliferation, GO-terms (GO:0030199, GO:0022617,
GO:0071711) linked to cellular rearrangements and GO-terms (GO:0060337, GO:2000551,
GO:0030853) related to immune system response. However a lot of significant GO-terms
Fig 5. Top20 significant enriched GO-categories for BL2 and RC. In all shown RNA-Seq and microarray strategies the visualized GO-categories were enriched (p-
value smaller than five percent and the pathway was bigger than four genes). The enrichment of GO-terms is shown in red: the higher the intensity of red, the lower the
p-value. For better scalability of colors the negative log 10 was chosen. The pathways agreeing the most amongst all pipelines are shown at the top.
https://doi.org/10.1371/journal.pone.0197162.g005
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could not be related to any of the expected cellular response classes. As previously discussed,
these results might be due to sequencing of total-RNA in case of the RC dataset in comparison
to polyA-mRNA sequencing. In addition, the biological variability of human patient data is
much higher in contrast to cell line data. Based on the data processed by P4 three GO-terms
were identified to be highly enriched (GO:0030574, GO:0030199, GO:0022617). These are
linked to (extra-)cellular rearrangements and fit well into our expectations, however could
only be detected with such high enrichment score based on P4. In comparison, P1-P3 look
very similar as the BL2 dataset.
Conclusion
This study presents a comparison of RNA-Seq specific pipelines as well as a cross comparison
with matched microarray data. For the investigated realistic datasets microarray analysis was
inferior to the used RNA-Seq analysis strategies and only a minor proportion of DEGs already
reported by Schrader et al. could reproduced. Pipelines P1 to P3 performed rather similar
when looking at the correlation results, with a small lead in regard to utilization of raw data for
P3. In contrast, P1 outperformed the rest in terms of the highest agreement with the other
pipelines in the detection of differentially expressed genes. Results from P4 varied a lot, pre-
sumably due to the use of the internal Cufflinks statistics in the tool suite.
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. Using RNA-Seq data for the detection of a panel of clinically relevant mutations 
3.2 Using RNA-Seq data for the detection of a panel of clinically
relevant mutations
Reference
A Wolff, J Perera-Bel, HU Schildhaus, K Homayounfar, B Schatlo, A Bleckmann, T Beißbarth:
Using RNA-Seq data for the detection of a panel of clinically relevant mutations. Studies in
Health Technology and Informatics 2018, DOI: 10.3233/978-1-61499-896-9-217
3.2.1 Summary and discussion
RNA-Seq became the most popular technology to detect the expression of genes and isoforms,
and members of the MetastaSys consortium raised the question if it is possible to detect
mutations reliably on RNA-Seq data, on top of DEA, resulting in a sub-project and this
publication. After the establishment of a standard pipeline (see 3.1) the next step was to
answer the question if RNA-Seq has the potential for a cost-effective identification of single
nucleotide variants (SNVs). For that reason, Wileup a tool written in Perl to call SNVs
in RNA-Seq for a tumour only sample set is presented. In this publication, the focus was
on a panel of 442 SNVs with high clinical interest. Furthermore, this was evaluated on a
matched dataset from RNA-Seq and DNA-Seq of 14 patients. SNVs detected in RNA-Seq
data by Wileup were compared to the clinical standard of calling mutations from tumour
samples and subtracting mutations from a blacklist found in normal samples of the same
patient. By doing that it is possible to make a distinction between somatic mutations (tumour
tissue-specific) and germline mutations (occur in every cell, therefore the normal samples)
without using prior knowledge. This experimental setup resulted in 42 samples, three samples
for each of the 14 patients (one DNA tumour tissue sample, one DNA blood sample as a
reference called normal and one RNA tumour sample). The last method to be compared
was detecting mutations in DNA-Seq without the support from samples of normals. The
complete experimental setup is illustrated in figure 3.1.
WES and RNA-Seq reads were quality assessed using fastqc. Amongst the 14 patients
where seven patients with brain metastases and seven patients with liver metastases. All
WES brain samples showed high duplication levels and a drop in quality at the end of
the reads due to high levels of contamination with Nextera adapters. Hence, TrimGalore-
0.4.3 (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) was ap-
plied to all brain samples. Between 11% and 38.4% of base pairs were trimmed.
For the analysis of the DNA-Seq data the WES paired-end reads were aligned against the
reference genome of Homo sapiens version GRCh38.91 with bowtie2 (version 2.2.3). Samtools
was used to create bam files, and Picard (version 2.0.1) to mark duplicates. Then, GATK
(v3.8.0) best practices were followed to perform read realignment (IndelRealigner) and base
recalibration (BaseRecalibrator). RNA-Seq single-end reads were aligned against the refer-
ence genome of Homo sapiens Ensembl Version GRCh38.91 with the splice-aware aligner
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Figure 3.1. Illustration of the collected samples of 14 patients as input for the DNA-Seq and RNA-Seq
based analysis. The blood samples and metastatic tissue samples were exome sequenced and used for somatic
and germline mutation calling, using either Mutect2 (somatic caller) or the Haplotype Caller of GATK
(germline caller). Furthermore, the metastatic tissue was also RNA sequenced and used for the mutation
calling via Wileup, resulting in a total of 42 samples sequenced.
STAR (v2.5.2b). Picard (version 2.0.1) was used to remove duplicates. Mutect2 (GATK
v3.8.0, beta version) to detect somatic variants in WES data using matched tumour-normal
samples (referred to as “clinical standard”) as well as only tumour samples (“tumour-only”
mode). Cosmic (version 83, Coding and Non Coding vcf files) and dbSNP (version 138) were
provided as input to Mutect2 to adjust the threshold for evidence of a variant in the normal
sample. To confirm germline mutations detected by tumour-only samples and variants found
only in the RNA-Seq samples, GATK Haplotypecaller (v3.8.0) with dbSNP (version 138)
was used.
For the analysis of RNA-Seq data Wileup (see figure 3.2) was used. After Quality Control,
alignment with STAR (v2.5.2b) and Duplicate removal Two modes are available for Wileup:
1) a complete mode, for this the mpileup function of Samtools is used to derive all nucleotide
bases at each position from the bam files in the RNA-Seq data, saved as mpileup format.
Then the distribution of bases in each position from the mpileup format is parsed, saved and
annotated with also parsed database information of CiVIC, ClinVar and Cosmic. Resulting
in a filtered output file of all annotated mutations found in at least one of the databases.
2) Panel mode, in which a list of 442 nucleotide positions is selected. They are predictive
(only drug responses) SNVs with implications for cancer therapy from both CGI and CIViC,
comprising somatic, germline and germline polymorphisms. Here the mpileup is done only
for these positions resulting in a speedup from 2 hours to roughly 15 minutes per bam file.
A minimum of three reads or 10% of the reads supporting the alternative variant is used
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Figure 3.2. Workflow for detecting mutations in RNA-Seq using Wileup.
as default threshold. The output comprises the distribution of bases at each position, the
decision whether the position contains an SNV, and the clinical annotations from CIViC and
CGI. As shown in figure 3.3A 109 SNVs were found in all samples by the three methods: 10
in the gold standard, 104 in tumor-only and 73 in the RNA-Seq. The 10 SNVs detected by
the clinical standard were also detected in WES tumor-only and RNA-Seq. As the primary
purpose of the clinical standard is to find somatic mutations only, it differs a little bit from
Wileup, as Wileup is also annotating germline and germline polymorphism with clinical
relevance on top. The highest overlap was found between WES tumor-only and RNA-Seq (68
SNVs). The 36 variants unique to the WES tumor-only analysis were undetected in RNA-Seq
due to low expression. The 5 variants unique to RNA-Seq were undetected in WES due to
high duplication levels but could be validated by using the Haplotype Caller from GATK on
the normal samples of the individual patients. Seven out of the eight validated mutations
from pathology (bottom color bar of the heatmap in figure 3.3B) could be reliably identified
by all three methods (shown as validated in dark green and dark violet in the heatmap).
The missing mutation E545K of PIK3CA could not be identified by any of the methods,
due to high duplication levels for WES and missing expression in RNA-Seq. Nonetheless,
all somatic SNVs detected by the clinical standard were also detected by tumour-only and
RNA-Seq (figure 3.3B).
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Figure 3.3. A) Venn diagram depicting the number of SNVs identified by each method across all samples
(T+N: Mutect2, Tumor+Normal samples, T: Mutect2, Tumor samples, R: Wileup RNA-Seq). In total 109
SNVs were found (29 unique mutations from the panel of 442 clinical relevant mutations). B) Heatmap
visualisation of 29 unique SNVs which were found by at least one of the methods in any of the 14 patients.
Wild Type (WT) mutations are shown light green and purple, mutations found by the methods are in green
and purple, mutation agreeing with the pathological annotation (validated) are marked in dark green and
purple. The details of the pathological mutations are described in the annotation bars at the bottom of the
figure. The origin of the mutation is annotated in the bar at the right sight of the heatmap.
In conclusion, RNA-Seq appears to be a reliable approach for detecting the selected
panel of SNVs with clinical relevance, as confirmed by the pathologically validated data (for
somatic variants) and by the analysis of normal WES samples (for germline variants). A high
overlap between RNA-Seq and tumour-only WES was shown. Previous studies reported high
numbers of false positives in RNA-Seq data, however, by using a whitelist of well-defined
SNVs this problem could be avoided. In this setting, detecting SNVs in RNA-Seq data is a
comparable approach to WES tumor-only; yet, in RNA-Seq, it is regarded as an additional
analysis next to DEA, which can be quickly performed (average of 11-15 min/sample) for
no extra biological sample cost. Of course, the user has to accept false negatives in non
expressed genes, but that is inherent to RNA-Seq data. For future implementations, it would
be essential to consider RNA editing processes as well as including indels in the analysis.
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Abstract.  Somatic  single  nucleotide  variants  (SNVs)  are  genomic  events  with
increasing  implications  in  cancer  treatment.  The  clinical  standard  for  SNVs
detection  is  whole  genome/exome  sequencing  (WGS/WES)  in  matched  tumor-
normal  samples.  Yet,  this  is  a  very  costly  approach  both  economically  and
biologically and very often only tumor samples are sequenced. On the other hand,
RNA  sequencing  (RNA-Seq)  is  the  most  popular  technology  to  study  gene
expression, and has also the potential for a cost-effective identification of SNVs as
an alternative to tumor-only WES. Here we present a method for the identification
of SNVs in tumor-only RNA-Seq data putting a special focus on a small panel of
clinically relevant  SNVs. For  evaluation purposes,  we analyzed matched tumor-
normal WES and tumor-only RNA-Seq data from 14 cancer patients. We compared
SNVs detected in i) RNA-Seq by our method, ii) WES tumor-only by Mutect2 and
iii) WES matched tumor-normal by Mutect2. We did a detailed evaluation for a
reduced panel of clinically relevant SNVs and reliably identified in RNA-Seq data
a subset of mutations for which we had pathological annotation. Hence, RNA-Seq
rises as a cost-effective option to detect in parallel gene expression as well as a
small panel of clinically relevant SNVs in research.
Keywords: RNA-Seq, SNVs, Mutect2, variant calling, GATK
1.  Introduction
Somatic single nucleotide variants (SNVs) are genomic events known to drive cancer.
Whole genome and exome sequencing (WGS, WES) in matched tumor-normal samples
are  the  clinical  standard  for  detecting  somatic  SNVs.  There  are  many  tools  for
identifying SNVs on WGS or WES data, thoroughly compared in different contexts [1-
3]. According to these studies, two tools outperform the rest: Mutect [4] and Varscan2
[5]. The first performs better at identifying SNVs with low allele frequencies, whereas
the latter detects the highest number of SNVs and outperforms any tool at positions
with high coverage. On the other hand, RNA sequencing (RNA-Seq) has become the
1 Corresponding Author, Tim Beissbarth, University Medical Center Göttingen, Humboldtallee 32 D-37073
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most popular technology -after replacing microarrays- to study gene expression. Unlike
microarrays, RNA-Seq can easily be used to detect alternative splicing, RNA editing,
fusion genes,  other  RNA species,  and, potentially,  SNVs. Calling somatic SNVs in
RNA-Seq data has been done in some studies by applying tools specific for WES/WGS
data  [6-8].  Besides  obvious  false  negatives  produced  in  regions  with  low  or  no
expression, these studies reported false positive SNV calls in RNA-Seq data mainly
due  to:  PCR  cycle  bias,  strand  bias,  RNA  editing  and  difficulty  to  align  the
transcriptome to the reference genome due to splicing. Sheng and colleagues tried to
address some of these issues both on DNA and RNA-Seq [9]. An added problem is the
fact  that  clinical  samples  are  usually  limited  to  tumor-only  profiling.  Detection  of
somatic SNVs in WES tumor-only samples is challenging and has been addressed with
machine learning approaches [10] or the use of whitelists and blacklists as in Mutect
[4]. However, the same has not yet been attempted for RNA-Seq data. All in all, its
cheaper cost compared to WES/WGS together with all its possible applications makes
RNA-Seq a technology with high interest  for clinical  use (e.g.  parallel  detection of
SNVs and functional activation of genes). It seems worthwhile developing a method to
call SNVs in RNA-Seq data optimized for a panel of well-known SNVs.In this study
we present a method to call  SNVs in RNA-Seq tumor-only samples.  We assess its
performance putting special  focus  on optimizing the method for  a  panel  of  known
SNVs with high clinical interest. We compare our method’s performance on a matched
dataset  comprising RNA-Seq and WES data.  We chose Mutect2 to detect  SNVs in
WES data.We compare the SNVs detected in RNA-Seq data by our method to tumor-
only and tumor-normal results by Mutect2. 
2.  Materials and Methods 
2.1.  Databases
The  panel  of  known  SNVs  with  high  clinical  interest  was  based  on  the  Clinical
Interpretation of Variants in Cancer (CIViC, version from 01/06/2017) [11] and Cancer
Genome Interpreter (CGI, downloaded on 11/09/2017, last updated 02/08/2017) [12].
In both cases, we filtered for SNVs predictive of drug response. Genomic coordinates
were  transformed  from hg19  to  hg38  built  using  the  rtracklayer  R package.  Both
databases  were  merged  by  aggregating  duplicate  entries.  The  panel  of  actionable
variants contains information on 442 variants in 92 genes.
2.2.  Collection of Patient Samples
Tissue samples were collected by the surgery departments of the University Medical
Center  Göttingen.  The collected  tissues  are  from seven  metastatic  brain  and seven
metastatic  liver  tumours  with  origin  from either  colorectal  or  breast  cancer.  Fresh
frozen tissue samples for WES and RNA-Seq were separated. From these 14 patients
we collected EDTA-blood for WES as well. EDTA-blood samples served as control
samples to differentiate between germline and somatic mutations. In total 42 samples
were sequenced, 3 samples per patient. The study is approved by the Ethics Committee
of the University Medical Centre Göttingen, application number 21/3/11 and 14/10/05.
2.3.  Data Preprocessing and Analysis
WES  and  RNA-Seq  reads  were  quality  assessed  using  fastqc
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  All  WES brain  samples
showed high duplication levels and a drop in quality at the end of the reads due to high
levels  of  contamination  with  nextera  adapters.  Hence,  TrimGalore-0.4.3
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)  was  applied  to  all
brain samples. Between 11% and 38.4% of base pairs were trimmed. WES paired-end
reads were aligned against the reference genome of Homo sapiens version GRCh38
with  bowtie2  (version  2.2.3).  Samtools  was  used  to  create  bam  files,  and  Picard
(version 2.0.1) to mark duplicates. Then, GATK (v3.8.0) best practices were followed
to  perform  read  realignment  (IndelRealigner)  and  base  recalibration
(BaseRecalibrator).  RNA-Seq  single-end  reads  were  aligned  against  the  reference
genome of Homo sapiens Ensembl Version GRCh38.91 with the splice-aware aligner
STAR (v2.5.2b). Picard (version 2.0.1) was used to remove duplicates.
We used Mutect2 (GATK v3.8.0, beta version) to detect somatic variants in WES
data using matched tumor-normal samples (referred to as “clinical standard” in the text)
as well as only tumor samples (“tumor-only” mode). Cosmic (version 83, Coding and
Non Coding vcf files) and dbSNP (version 138) were provided as input to Mutect2 to
adjust  the  threshold  for  evidence  of  a  variant  in  the  normal  sample.  To  confirm
germline mutations detected by tumor-only samples, GATK Haplotypecaller (v3.8.0)
with dbSNP (version 138) was used.
3.  Results
3.1.  Detection of SNVs in RNA-Seq Data
For  calling  RNA-Seq  specific  mutations  we  implemented  a  variation  of  pileuping
nucleotide bases at each position in the transcriptome, utilizing mpileup from samtools.
In case all possible mutations in the RNA-Seq data should be checked, a mpileup of all
base positions in the RNA-Seq data is performed. Afterwards the distribution of bases
in  each  position  is  saved  and  evaluated  to  annotate  them  at  positions  where
supplemental database information (CIVIC, ClinVAR, Cosmic), parsed accordingly in
the script, is available. In case the -panelmode flag is selected, a list of 442 nucleotide
positions is selected and the mpileup is called only for these positions. A minimum of 3
reads  or  10%  of  the  reads  supporting  the  alternative  variant  are  used  as  default
thresholds. The output comprises the distribution of bases at each position, the decision
whether the position contains an SNV, and clinical annotations from CIViC and CGI. 
The possibility to detect well-known SNVs with very little extra effort in RNA-
Seq data is of high interest. For that, it is crucial to define the set of SNVs one wants to
detect. In this study we designed a panel that covers a curated list of variants with a role
in  treatment  response  (i.e.  biomarkers  of  drug  response).   The  panel  is  used  as  a
whitelist of mutations known to have implications in cancer therapy. It comprises 442
SNVs and on 92 genes.  The variants  can have different  origins:  somatic,  germline
mutations or germline polymorphisms.  
3.2.  Comparison of WES and RNA-Seq Data in Detecting SNVs
We generated WES matched tumor-normal  and RNA-Seq tumor-only data from 14
cancer  patients.  We  applied  a  standard  pipeline  to  detect  somatic  SNVs  in  WES
matched tumor-normal  samples,  referred  to  as  clinical  standard.  We also applied a
tumor-only  mode  to  WES  tumor  samples,  referred  to  as  tumor-only.  Finally,  we
applied our method to detect SNVs in RNA-Seq tumor samples. SNVs detection was
focused on 442 cancer-specific variants with clinical interest. 
As shown in Figure 1A we found 109 SNVs in all samples by the three methods:
10 in the gold standard, 104 in tumor-only and 73 in the RNA-Seq (average of 0.7, 7.4
and 5.2 SNVs/sample, respectively).  The 10 SNVs detected by the clinical standard
were  also  detected  in  WES tumor-only and  RNA-Seq. We found  a  higher  overlap
between WES tumor-only and RNA-Seq (68 SNVs) than between the two methods on
WES (10 SNVs). This finding is explained by the fact that our panel includes germline
mutations  and  polymorphisms;  the  clinical  standard  is  optimized  to  reliably  detect
mutations only present in the tumor sample by filtering out any mutation present in the
normal sample. Accordingly,  the clinical standard only detected SNVs known to be
somatic. Nonetheless, all somatic SNVs were also detected by tumor-only and RNA-
Seq (Figure 1B).
Figure 1:  A) Venn diagram depicting the number of SNVs identified by each method across all samples
(T+N: Mutect2, Tumor+Normal samples, T: Mutect2, Tumor samples, R: Wileup RNA-Seq). In total 109
SNVs were found  (29 unique  mutations  from the panel  of  442 clinical  relevant  mutation).  B) Heatmap
visualization of 29 unique SNVs which were found by at least one of the methods in any of the 14 patients.
Wild Type (WT) mutations are shown light green and purple, mutations found by the methods are in green
and purple, mutation agreeing with the pathological annotation (validated) are marked in dark green and
purple. The details of the pathological mutations are described in the annotation bars at the bottom of the
figure. The origin of the mutation is annotated in the bar at the right sight of the heatmap. 
The variants uniquely detected by WES tumor-only (36 SNVs) could be explained
in the majority of the cases  due to low expression in the RNA-Seq data.  The only
exception presenting high expression was the MGMT promoter SNP rs16906252. Yet,
this  SNP is  known to be  associated  with low MGMT expression,  leading  to  allele
specific expression [13]. On the other hand, only 5 SNVs were exclusively detected by
RNA-Seq.  Two of them -  TPMT  Y240C and  TPMT  A154T -  are  known to be an
haplotype of the TPMT enzyme (TPMT*3A) [14] and were indeed found in the same
patient (BM4). These haplotype was not confirmed by WES tumor-only due to high
duplication levels, which did not pass Mutect2 filters. The other three mutations (ETS2
mutation in patient BM1, NQO1 in patient BM7 and XRCC1 mutation in patient LM3)
were not found in WES tumor-only also due to the same reason. As a matter of fact,
these  5  germline  polymorphisms  detected  exclusively  in  RNA-Seq  data  could  be
confirmed by a germline SNV caller (Haplotypecaller) in normal samples. 
We had pathological data on 4 routinely tested biomarkers (BRAF,  KRAS,  NRAS
and PIK3CA) as part of the dataset. 7 out of the 8 pathologically validated mutations
were consistently detected by the three methods (Figure 1).  PIK3CA E545K mutation
in patient LM5 was not detected by any method; WES data presented high duplicated
regions in that position, whereas in RNA-Seq data PIK3CA was not expressed. 
4.  Discussion
We showed a high overlap between RNA-Seq and tumor-only WES. Previous studies
reported  high  numbers  of  false  positives  in  RNA-Seq  data,  however,  by  using  a
whitelist of well-defined SNVs we avoid this problem. In this setting, detecting SNVs
in RNA-Seq data is a comparable approach to WES tumor-only; yet, in RNA-Seq it is
regarded  as  an  extra  analysis  which  can  be  quickly  performed  (average  of  11-15
min/sample)  for  no  extra  cost.  More  important,  RNA-Seq appears  to  be  a  reliable
approach for detecting the selected panel of clinically relevant SNVs, as confirmed by
the pathologically validated data (for somatic variants) and by the analysis of normal
WES samples (for germline variants). Of course, the user has to accept false negatives
in  non  expressed  genes,  but  that  is  inherent  to  RNA-Seq  data.  For  future
implementations, it would be important to consider RNA editing processes as well as
including indels in the analysis.
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3.3.1 Summary and discussion
In this publication, the resulting standard pipeline consisting of STAR, RSEM, edgeR and
topGO of the first publication 3.1 were applied on a dataset of mice having one million
Colorectal cancer (CRC) cells of cell line CMT-93 injected into the liver, as a novel syngeneic
and orthotopic mouse model of CRC liver metastasis. By using RNA-Seq data it was possible
to evaluate the difference in the expression profile of the cell line when migrating into the
liver to become metastases. The tumour-free liver samples were used as a blacklist for liver
tissue-specific expression, which does not occur in the cell line. Next, to standard quality
checks on the sequencing data itself, quality checks on the count data showed a higher
separation of the tumour samples (figure 3.4). After further investigations by checking either
liver or colorectal tissue-specific gene expression, it could be shown, that three of the samples
represented false biopsies and were excluded due to massive infiltration with liver (4 to 20
times the expression of liver enzymes) and low content of the colorectal tissue. This resulted
in an experimental setup of 3 sample replicates of the cell line CMT93, seven biological
replicates of normal liver and four biological replicates of the metastatic tissues in the liver.
After mapping with STAR and read counting with RSEM, edgeR was used to detect DEGs,
comparing CMT-93 cells with the liver metastases. Afterwards, a geneset for gene ontologies
was defined consisting of all the DEGs identified by the comparison mentioned above. The R
package topGo was used to identify over- or under-represented GO terms using the weighted
Fisher-exact test algorithm from the package.
This analysis resulted in a total of 3329 (1174 down-regulated (35%), 2155 up-regulated
(65%) )) DEGs. The top five dysregulated genes were matrix metallopeptidase (MMP) 7,
keratin 20 an epithelial colorectal cancer marker, Wnt inhibitory factor 1, MMP 9, and
chemokine receptor 4. Furthermore, the Gene ontology analysis gave a more precise picture
of the significant genes related to functional groups. The top changes of the cell line, when
emitted into the liver tissue, where differences in gene expression related to inflammatory
response, angiogenesis and signal transduction, positive regulation of transcription from
RNA polymerase II promoter, transmembrane receptor protein tyrosine kinase signalling
 3 Cumulative part of the dissertation
Figure 3.4. PCA plot with the original data, showing parts of the tumour samples shifted towards normal
liver samples.
pathway, and positive regulation of ERK1 and ERK2 cascade. The complete and in-depth
interpretation of the results supporting an invasion-metastasis cascade with notable changes
in the expression profile can be found in the discussion part of the paper.
In conclusion, the bioinformatical approaches applied here where a crucial step for linking the
most-relevant metastasis-related genes to reveal, that the liver environment stimulates the
CMT-93 cells into the expression of metastasis enhancing genes. These genes were associated
with tissue remodelling, cell proliferation, adhesion, wnt activity, transcription/regulation,
and inhibition of apoptosis.
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Abstract
Background: Colorectal cancer (CRC) is the second leading cause of cancer-related death in men and women.
Systemic disease with metastatic spread to distant sites such as the liver reduces the survival rate considerably.
The aim of this study was to investigate the changes in gene expression that occur on invasion and expansion
of CRC cells when forming metastases in the liver.
Methods: The livers of syngeneic C57BL/6NCrl mice were inoculated with 1 million CRC cells (CMT-93) via the
portal vein, leading to the stable formation of metastases within 4 weeks. RNA sequencing performed on the
Illumina platform was employed to evaluate the expression profiles of more than 14,000 genes, utilizing the
RNA of the cell line cells and liver metastases as well as from corresponding tumour-free liver.
Results: A total of 3329 differentially expressed genes (DEGs) were identified when cultured CMT-93 cells
propagated as metastases in the liver. Hierarchical clustering on heat maps demonstrated the clear changes
in gene expression of CMT-93 cells on propagation in the liver. Gene ontology analysis determined inflammation,
angiogenesis, and signal transduction as the top three relevant biological processes involved. Using a selection
list, matrix metallopeptidases 2, 7, and 9, wnt inhibitory factor, and chemokine receptor 4 were the top five
significantly dysregulated genes.
Conclusion: Bioinformatics assists in elucidating the factors and processes involved in CRC liver metastasis.
Our results support the notion of an invasion-metastasis cascade involving CRC cells forming metastases on
successful invasion and expansion within the liver. Furthermore, we identified a gene expression signature
correlating strongly with invasiveness and migration. Our findings may guide future research on novel therapeutic
targets in the treatment of CRC liver metastasis.
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Background
Colorectal cancer (CRC) is the third most common type
of cancer in the Western world and the second most
common cause of cancer-related death in both genders.
The overall relative 5-year survival of CRC patients is
approximately 50% [1]. Almost half of all patients suffe-
ring from CRC are confronted with liver metastasis
either at the time of diagnosis (15 to 20%), or later du-
ring the course of the disease (25%) [2]. Given the rather
poor 5-year survival rate of patients who develop liver
metastasis (approx. 30%), it is vital that we develop and
evaluate new therapeutic strategies. In particular, the
knowledge of molecular changes to CRC cells that end
up in the liver may enable us to search for new target
options far more selectively.
Metastasis is frequently a final and fatal step in the
progression of solid malignancies. The nature and time
of onset of the changes that provide tumour cells with
metastatic functions are still largely unknown. Further-
more, there has been an ongoing debate to this end for
more than a 100 years. In 1889, Stephen Paget noticed
that the pattern of metastases produced by different
neoplasms was not random. In his ‘seed and soil’ hy-
pothesis, Paget claimed that certain tumour cells (‘seeds’)
have an affinity for the microenvironment of specific or-
gans (‘soil’), and only when the ‘seed’ and the ‘soil’ are
compatible can metastasis occur [3].
With respect to the “seed”, it is widely accepted these
days that cancer is attributed to the accumulation of
genetic alterations in cells. Thus, to understand the mo-
lecular mechanisms of cancer metastasis, it is indispen-
sable to identify not only the genes whose alterations
accumulate during cancer progression but also those
genes whose expression is responsible for the acquisition
of metastatic potential in cancer cells [4]. Indeed, com-
parative analyses of the gene expression profiles of meta-
static and non-metastatic cells have revealed that various
genes are differentially expressed in association with the
metastatic potential of cancer cells [4]. Conversely, the
existence of genes expressed by rare cellular variants
that specifically mediate metastasis has been disputed
[5]. Transcriptomic profiling of primary human carcin-
omas has identified gene expression patterns that, when
present in the primary tumour, predict a poor prognosis
for patients [6, 7]. The existence of such signatures can
be interpreted in the sense that genetic lesions acquired
early on in tumorigenesis may prove sufficient for the
metastatic process, and that consequently no metastasis-
specific genes exist.
There is growing evidence that the development of or
progression to metastases is also dependent on the
“soil”. Tumour cell circulation, extravasation into a dis-
tant organ, angiogenesis, and uninhibited growth also
provide essential hints as to the metastatic process [8].
The molecular requirements for some of the steps in-
volved may be highly tissue specific. For example, the
proclivity that tumours have for specific organs, such as
breast carcinomas for bone and lung, was noted more
than a century ago [9]. Moreover, the potential of
tumour cells to metastasize depends on their interaction
with homeostatic factors in the target organ that promote
tumour-cell growth: survival, angiogenesis, invasion, and
progression. It seems that the intrinsic cellular heteroge-
neity within tumour populations evolves through an
extrinsic selection process, which is based on more or less
infrequent cellular variants with augmented metastatic
abilities and which finally mediates the outgrowth in
distant sites [9]. Of note, the mechanism that enables the
liver microenvironment to influence the behaviour of
CRC cells is still only poorly understood.
The most common site for CRC metastasis is the liver
[10]. Many patients still suffer from recurrence of the
primary and/or distant metastasis, even after undergoing
liver resection combined with adjuvant approaches such
as chemo- and radiotherapy. Nonetheless, only a minority
of patients actually survive for years [11]. Therefore, the a
priori or early inhibition of metastasis could prove to be a
key step towards the curative treatment of patients. We
have to assume that each organ places different demands
on circulating cancer cells for the homing and subsequent
outgrowth of metastases.
To clarify this issue, we established a novel syngeneic
and orthotopic mouse model of CRC liver metastasis. This
model comprises the injection of cells from a known CRC
cell line to mimic the spread of the primary tumour and
thus to investigate the invasion and expansion of CRC
cells in the liver on the gene expression level. The goal
here was to identify genes that contribute to this process
of adapting to the new “soil” and thereby the metastatic
progression of the disease. The fundamental aim of the
study was to identify new candidate markers or molecular
mechanisms in the diagnosis of liver metastasis resulting
from CRC, as well as therapeutic targets effectively inhi-
biting CRC metastasis in the liver.
Methods
Reagents and antibodies
Unless specified otherwise, all chemicals and reagents
were supplied by Life Technologies (Darmstadt,
Germany). Foetal Bovine Serum Superior (FBS) was pur-
chased from Biochrom (Berlin, Germany) and trypsin
10-fold was supplied by PAA (Pasching, Austria). Anti-
bodies for immunolabelling purposes were purchased
and used as illustrated in Table 1.
Cell lines and culture
The cell line CMT-93 (isolated from a mouse colorectal
adenocarcinoma) was kindly donated by Christina Hackl
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and her workgroup in Regensburg, Germany. On testing,
the cells were found to be negative for mycoplasma by
RT-PCR.
CRC cells were expanded and stored in frozen aliquots
(− 70 °C). After thawing, the cells were routinely cul-
tured in 75 cm2 culture flasks in DMEM high glucose,
supplemented with 10% FBS, 1% L-glutamine, 1% so-
dium pyruvate and 1% penicillin/streptomycin at 37 °C
and 5% CO2 in a humidified incubator. Tumour cells
were passaged once (following 3 days in culture), cul-
tured for a further 4 days, and then trypsinized for sub-
sequent implantation studies. Tumour cells from the
same passage were used for all the implantation experi-
ments. Additionally, aliquots of the cell line were snap
frozen and processed for transcriptome sequencing
analysis (RNA-seq).
Animals and procedures
Ten-week-old female C57BL/6NCrl mice (mass 18–22 g)
were purchased from Charles River (Sulzfeld, Germany).
Animals were kept on a 12-h day/night rhythm and
fed with a phytoestrogen-reduced mouse diet (ssniff,
Soest, Germany).
Prior to (surgical intervention) surgery, animals received
a subcutaneous application of carprofen (Rimadyl®, Pfizer,
Berlin, Germany) (5 mg/kg body mass). Animals were
anaesthetized under constant sevoflurane inhalation
(Sevorane®, Abbott, Wiesbaden, Germany). After median
laparotomy, the hilum of the liver was exposed to access
the portal vein. One million tumour cells in a volume of
100 μl PBS buffer were injected slowly into the portal vein
using a 30 G needle.
In the study group, seven animals were implanted with
tumour cells. The control group encompassed five ani-
mals which underwent the same procedures (sham-OP),
but were only injected with buffer solution. All animals
were sacrificed after 4 weeks. Explanted livers were
sliced for macroscopic assessment, photographic docu-
mentation of the section planes, and further processing.
Tissue samples from the tumour core of the liver me-
tastases derived from CMT-93 as well as matched
unharmed liver tissue (macroscopically tumour-free
liver) were excised, snap frozen for whole transcriptome
sequencing analysis (RNA-seq), or frozen in 2-
methylbutane at −70 °C for immunolabelling.
Immunolabelling
Cryostat sections (5 μm) were fixed in ice-cold acetone
for 10 min and were stored at −80 °C. After rehydration
in Tris/HCl buffer (pH 7.6), sections were incubated
with the primary antibodies (see Table 1) overnight at
4 °C. Endogenous peroxidase was inactivated by incu-
bation with 0.3% H2O2 in 70% methanol and 30%
Tris/HCl buffer for 20 min at RT. The HRP-labelled
goat anti-rabbit IgG secondary antibody (DakoCytomation
K4002, Carpinteria, USA, ready-to-use reagent) was used
to identify β-catenin, Ki-67, E-cadherin, and vimentin. To
immunolabel CD44, sections were exposed to an avidin/
biotin blocking step (Life Technologies, Darmstadt,
Germany) followed by incubation with the primary anti-
body (overnight at 4 °C). This antigen was identified by
the secondary antibodies donkey anti-rat biotinylated
(1:200, 1 h at RT) and avidin-horseradish peroxidase
(HRP) (1:400, 1 h at RT). 3-amino-9-ethyl-carbazole
(AEC) solution (BD Pharmingen, Heidelberg, Germany)
and haematoxylin counterstaining were used for
visualization by light microscopy. Negative controls were
carried out for each antibody by omitting the primary
antibody from the protocol. Samples were covered with
50 μl of the aqueous mounting agent Aquatex (Merck,
Darmstadt, Germany) and evaluated under a light micro-
scope (LEICA DM IRE2, Bensheim, Germany).
RNA isolation
For RNA sequencing purposes (RNA-seq), three aliquots
of the cell line and specimens (tumour core and liver)
from seven animals were collected. The RNA puri-
fication system PeqGold TriFast (Peqlab, Erlangen,
Germany) was used to isolate RNA from metastatic liver
tissue. Briefly, specimens were defrosted in peqGold
TriFast (1 ml/100 mg tissue) and then homogenized
using TissueLyser LT (Qiagen, Hilden, Germany) at
Table 1 Antibodies used in immunolabelling analysis
Antigen Species Dilution Catalogue Manufacturer
β-catenin Rabbit 1:50 14–6765 eBioscience, Frankfurt a.M., Germany
CD44 Rat 1:1000 550,538 BD Pharmingen, Heidelberg, Germany
Ki-67 Rabbit 1:200 275R-14 Cell Marque, California, United States
E-cadherin Rabbit 1:50 sc-7870 Santa Cruz Biotechnology, Heidelberg, Germany
Vimentin Rabbit 1:1000 ab92547 Abcam, Cambridge, UK
Anti-rat biotinylated Donkey 1:200 RPN1004 GE Healthcare, Freiburg, Germany
Avidin HRP 1:400 18–4100-94 eBioscience, Frankfurt a.M., Germany
HRP Labelled anti-rabbit Goat Ready to use K4002 Dako, Hamburg, Germany
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50 Hz. Total RNA was isolated according to the manu-
facturer’s instructions and stored at −80 °C. In addition,
the High Pure RNA Isolation Kit (Roche, Grenzach-
Wyhlen, Germany) was used to isolate RNA from CMT-
93 cells according to the manufacturer’s recommenda-
tions. The quantity and integrity of the isolated RNA was
assessed in a NanoDrop ND − 1000 spectrophotometer,
version 3.5.2 (Peqlab, Erlangen, Germany), using the
260 nm/280 nm absorbance ratio and was further ana-
lysed with an Agilent 2100 BioAnalyzer (Agilent Tech-
nologies, Santa Clara, California, USA) as a quality check.
RNA-seq was performed at the Transcriptome and Gen-
ome Analysis Laboratory in Goettingen, Germany, using
an Illumina HiSeq2000 sequencer (Illumina, Inc., San
Diego, California, USA).
Deep sequencing analysis
As starting material for the library preparation, 0.5 μg
of total RNA was used. The libraries were generated
according to the TruSeq mRNA Sample Preparation
Kits v2 Kit from Illumina (Cat. N°RS − 122-2002). The
fluorometric based QuantiFluor™ dsDNA System from
Promega (Mannheim, Germany) was used for accurate
quantitation of cDNA libraries. The size of final cDNA
libraries was determined by using the Fragment
Analyzer from Advanced Bioanalytical. cDNA libraries
were amplified and sequenced by using the cBot and
HiSeq2000 from Illumina (SR; 1 × 50 bp; ca. 30 Mio
reads per sample). Sequence images were transformed
to bcl files using Illumina software BaseCaller, which
were demultiplexed to fastq files with CASAVA v1.8.2
and quality checks were done via fastqc.
Statistics
Preparation of data/statistical model
An in-house RNA-seq analysis pipeline employing the
STAR-aligner (version 2.4.0 h) [12] for the mapping and
counting of reads with the expectation-maximization
algorithm implemented in the software package RSEM
(version 1.2.19) [13] was used for counting reads.
Ensembl Mus musculus GRCh38 Version 78 was con-
sidered as the reference for mapping and further
annotations.
Following RNA-seq, all seven tumour probes derived
from CMT-93 underwent quality control measures.
Employing the corresponding RNA-seq data, they were
checked for the expression of CK 20 as surrogate parameter
for colorectal tissue or liver-specific gene expression to
identify liver-specific genes, such as phosphoenolpyruvate-
carboxykinase 1 (PCK1), cytochrome p450 (CYP), and car-
bamoyl phosphate synthase1 (CPS1). Three tumour probes
(D213K, D214K, D215K) representing false biopsies were
excluded from further analysis owing to a strong infiltration
of liver (approx. 4 to 20 times the elevated expression levels
of liver enzymes) and low content of colorectal tissue.
Principal component analysis (PCA) was performed in
R, the programming language and environment (version
3.2), to visualize the underlying structure of the dataset
by calculating the eigenvectors and plotting those two
components with the highest variance in the data.
Focussing on the comparison between the cell line
and metastases, we filtered out differential genes spe-
cific to liver tissue, which we considered as ‘liver tissue
effect’. Thus, differentially expressed genes (DEGs)
were identified as either up- or down-regulated when
comparing the CMT-93 cell line with the unharmed
liver tissue. Subsequently, these differences relating to
the normal liver background were excluded from the
gene expression results between the cell line and liver
metastases. This filtering step was done in order to
identify genes representing differences in cell line ver-
sus tumour, instead of general differences in cell lines
versus normal liver.
Significant differential gene analysis
Basing on the read counts attained from RSEM, the R
package EdgeR [14] was used to calculate the mean
intensities as well as the p-value and the log fold
change (logFC) for each DEG, comparing the CMT-93
cells with the liver metastases formed. Thus, gene dif-
ferences between the two groups were identified by fit-
ting a negative binomial generalized linear model
implemented in EdgeR. Expression results were re-
ported as mean transcripts per million (TPM) values
for each group.
A list was created comprising 119 genes associated
with metastasis, based on the genes described in the
Tumor Metastasis RT2 Profiler PCR Array by Qiagen
Hilden, Germany (Additional file 1). This list was ap-
plied as a filter following completion of the analysis of
the DEGs to profile the expression of these genes in our
dataset.
Gene ontology (GO) analysis
A gene set was defined, comprising all the DEGs
identified in the comparison of CMT-93 cells and
the liver metastases that formed, corrected for the
liver background and with a false discovery rate of
less than 5% (FDR < 0.05). This gene set was
employed in the gene ontology and pathway analysis.
This method, implemented in the R package topGO [15],
allows us to identify GO terms that are over-represented
(or under-represented) using the annotations for that gene
set taken from the Gene Ontology Database (http://
www.geneontology.org/). The significant level of GO terms
for the DEGs was analysed with the weighted Fisher’s exact
test in the package. We computed p-values for all the
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DEGs in the GO category “biological processes”; the
threshold of significance was defined as p-value <0.05.
Results
Syngeneic mouse model of CRC metastasis in the liver
Following the injection of CMT-93 cells via the portal
vein and their subsequent expansion, 70–80% of animals
developed liver metastases in any number of liver lo-
bules during the course of the study, as seen on macro-
scopic assessment (Fig. 1a). Within the life span of the
animals, CMT-93 cells had colonized about 30–50% of
the mouse liver with the tumour spots increasing to ap-
proximately 5 to 10 mm in diameter. However, the
spread of the tumour burden resulting from CMT-93
proved to be inhomogeneous when comparing the right
and left liver lobules of injected mice. On the micro-
scopic level, immunohistochemical staining 4 weeks
after tumour cell injection into the portal vein was used
to assess phenotypic expression of colorectal carcinoma
markers. Liver metastases displayed features of a mode-
rately differentiated colorectal adenocarcinoma revealing
complex glandular structures (40–75% gland formation)
in a desmoplastic stroma (Fig. 1 b, c). An important fea-
ture of invasion is the presence of this desmoplasia or
desmoplastic reaction, a type of fibrous proliferation
surrounding tumour cells and secondary to the invasive
tumour growth. The glandular structures expressed
epithelial markers such as membrane-bound β-catenin
(Fig. 1d) and E-cadherin (Fig. 1e). The latter was
expressed mostly in the cytoplasm, which indicates that
this wnt marker was inactive. The hyaluronic acid recep-
tor CD44 (a putative marker of ‘stemness’ in CRC) was
also present and staining was detected in nearly all of
the tumour cells we investigated (Fig. 1f ). The unsystem-
atic arrangements of gland formations also expressed the
mesenchymal marker vimentin (Fig. 1g). The proliferation
marker Ki-67 was expressed abundantly in more than 75%
of all liver tumours in a random pattern (Fig. 1h).
Adaptation of CMT-93 cells when forming metastases in
the liver
To assess the factors involved in the formation of liver
metastases, we performed RNA-seq analysis on both the
liver metastases as well as unaffected liver tissue. Figure
2 summarizes the structure of the gene expression data.
The first principal component (PC) is plotted on the x-
axis and captures 74% of the variance. The second PC is
plotted on the y-axis and captures 19% of the variance.
The PCA plot clearly portrays the separation of the
CMT-93 cell line samples from those of the correspon-
ding macroscopically tumour-free liver, as well as from
the derived liver metastases. As assumed, the cluster
associated with CMT-93 was found to be located in
close proximity to the cluster relating to the derived
Fig. 1 Macroscopic and microscopic aspects of liver metastases derived from CMT-93. Macroscopic overview of metastatic growth 4 weeks
following implantation of CMT-93 cells via the portal vein in syngeneic C57BL/6NCrl mice (treatment group). Explanted livers were sliced
for macroscopic assessment (a) and subjected to H&E staining (b, c). Liver metastases represented a moderately differentiated colorectal
adenocarcinoma revealing complex glandular structures (50–75% gland formation) in a desmoplastic stroma. Subpanel d depicts the results of
immunolabelling to detect ß-catenin (the inlay illustrates the mostly cytoplasmic location of expression) and e confirms E-cadherin, both markers indicative
of the glandular structures. The dedifferentiated/mesenchymal differentiation was identified by staining with anti-vimentin (g) and anti-CD44 (f). Ki-67 was
used as a proliferation marker as illustrated in h Scales are as indicated
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metastases. We also plotted liver specimens originating
from sham-operated animals (injection of buffer alone).
When overlaid on the PCA plot in Fig. 2, these samples
lay in exactly the same position as the cluster of the
macroscopically tumour-free liver samples (data not
illustrated).
Table 2 lists the DEGs during the propagation of
CMT-93 cells in the liver. A total of 5297 genes were
down-regulated and 6597 were up-regulated when
CMT-93 cells propagated in the liver. The elimination of
DEGs relating to the liver background (see materials and
methods) reduced the total number of DEGs to 1174
down-regulated genes (35%) and 2155 up-regulated
genes (65%).
The results of hierarchical cluster analysis to assess
the relatedness of the 120 DEGs displaying the greatest
differences in expression are presented in Fig. 3. The
heat map reveals systematic and fairly clearly distin-
guished variations in the expression of genes between
the original CMT-93 cells, the derived liver metastases,
and tumour-free liver. Of note, the changes in expres-
sion of the CMT-93 cells outgrowing as liver metastases
is clearly apparent. However, the hierarchical clusters re-
lating to the metastases and the tumour-free liver are
somewhat closer to each other owing to the fact that the
implanted CMT-93 cells forming metastases infiltrate
the liver tissue. The gene expression profile is therefore
bound to reflect the colonization of the hepatic tissue.
We then applied a filter set of 119 selected genes asso-
ciated with metastasis to our RNA-seq data set following
the elimination of DEGs determining the liver back-
ground. Thus, 32 relevant genes were identified with a
threshold of FDR < 5%, of which 23 were up-regulated
and 9 down-regulated. Additional file 2 contains the
count data of the samples. Figure 4 illustrates the heat
map of the filtered DEGs within the CMT-93 cell line
and the liver metastasis samples. Hierarchical clustering
confirmed the clear changes between DEGs of the
CMT-93 cells and the derived metastases. Table 3 pre-
sents an overview of these genes which were also ranked
by p-value. The top five dysregulated genes were found
to be matrix metallopeptidase (MMP) 7, keratin 20 as an
epithelial marker of colorectal carcinoma, wnt inhibitory
factor 1, MMP 9, and chemokine receptor 4.
With respect to functional gene groups, the 23 up-
regulated genes were attributed to extracellular matrix
proteins (6 genes), cell growth and proliferation (5 genes),
cell adhesion (4 genes), wnt signalling (3 genes), tran-
scription factors/regulators and epithelial-mesenchymal
transition (EMT) (2 genes each), and CRC-related genes
(1 gene). The 9 down-regulated genes were assigned to
cell growth and proliferation, wnt signalling and
Fig. 2 PCA was used to visualize the underlying structure of the dataset. CMT-93 cells as well as tumour probes (tumour liver tissue) formed
clusters clearly separate from the corresponding macroscopically tumour-free liver. Each group was tightly clustered
Table 2 Differences in gene expression among the sample groups (DEGs)
CMT-93 vs. liver metastases Macroscopic-free liver vs.
liver metastases
CMT-93 vs. macroscopic-free liver CMT-93 vs. liver metastases
corrected for the liver background
−1 = down-regulated 5297 5163 5764 1174
0 = unregulated 3667 4157 2684 0
1 = up-regulated 6597 5749 6187 2155
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Fig. 3 (See legend on next page.)
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transcription factors/regulator (2 genes each), as well as
apoptosis genes, extracellular matrix proteins, and EMT
(1 gene each).
Biological processes involved
To address the pathways and processes involved, signifi-
cant DEGs with FDR < 5% were selected and tested
against the background set of all genes with GO annota-
tion (Fig. 5). The most relevant GO terms for biological
processes enriched were “inflammatory response”,
“angiogenesis”, “signal transduction”, “positive regulation
of transcription from RNA polymerase II promoter”,
“transmembrane receptor protein tyrosine kinase signal-
ling pathway”, and “positive regulation of ERK1 and
ERK2 cascade”.
Discussion
CRC is a common disease whose considerable metastatic
potential highlights the urgency and necessity to develop
novel therapeutic approaches to prevent or treat tumour
progression and metastasis. In this study, we set out to
analyse the changes in gene expression and pathways
that play a role in the colonisation of mouse liver by the
cell line CMT-93, mimicking the processes that lead to
the ultimate formation of liver metastases secondary to
CRC. To this end, we first had to establish the in vivo
metastatic mouse model. CMT-93 cells demonstrate a
strikingly efficient tumorigenic capacity following their
implantation via the portal vein, the common route CRC
cells take when colonising the liver. Furthermore, the
CMT-93 cell line originated from the mouse strain we
employ, C57BL/6NCrl; the two are thus syngeneic and
this enables us to circumvent rejection responses as
complications. Moreover, the mice are immunocompe-
tent, which allows us to investigate the normal inflam-
matory response to tumour growth. Of note, the
outgrowing metastases in this model are reproducible
and display a number of prototypic features (structure
and markers) common to human CRC liver metastases.
The model itself acts as a paradigmatic proof of
principle for genetic alteration when forming liver me-
tastases. A xenograft model involving human CRC cell
lines would not have been able to fulfil our criterion of
immunocompetence to mimic the seed and soil theory
in humans. While searching for suitable models we tried
three combinations in total, based on literature research
and commercial availabilities. Although CT-26 (ATCC®
CRL-2639™) and the mouse strain Balb/c resulted in
tumour formation in the liver, these were found to be
mesenchymally de-differentiated in nature. The cell line
APC1638-NT (kindly donated by Prof. R. Smits, Rotter-
dam, Netherlands) with mouse strains C57BL/6 N or
C57BL/6 J resulted in no detectable tumour growth
whatsoever (data not shown). The CMT-93/C57BL/
6NCrl model proved to be the only one demonstrating
reproducible liver metastatic growth with the histo-
logical features of colorectal cancer.
Disseminating tumour cells need to adapt to sur-
rounding tissues in a continuous fashion [16]. For ex-
ample, CRC cells of the primary tumour have to avoid
succumbing to any immune response, detach from the
primary, migrate into the portal system, arrive in the
liver, traverse the endothelial barrier of the portal vessels
(extravasation), overcome hypoxia on integration into
the liver parenchyma, adapt to the new environment,
initiate angiogenesis, and finally expand as metastases
(metastatic colonisation) [17–19]. Taken together, these
numerous influences during the process of metastatic
spread into clinically detectable macroscopic disease lead
to marked changes in gene expression. This new gene
signature is the result of a multi-step process in which
carcinoma cells progress along the “invasion-metastasis
cascade” [18]. The results of our study visibly support
the notion that CRC cells certainly undergo a number of
clear changes in the liver environment.
It goes without saying that every single finding from
the dataset following RNA-seq analysis cannot be com-
mented on in this highly specific context during propa-
gation in the liver. However, there are some definite
hints as to which genes and pathways have to be ad-
dressed when aiming to treat CRC liver metastasis.
Our RNA-seq expression analysis and subsequent fil-
tering with the selection list of the most-relevant
metastasis-related genes reveals that the liver environ-
ment stimulates CMT-93 cells into expressing a number
of genes enhancing metastasis. These genes are associ-
ated with functions such as tissue remodelling, cell pro-
liferation, adhesion, wnt activity, transcription/
regulation, and inhibition of apoptosis, which all contrib-
ute to metastatic activity and tumour cell invasion.
(See figure on previous page.)
Fig. 3 Top 120 DEGs between CMT-93 cells, liver metastases derived from CMT-93 and macroscopically tumour-free liver. Expression data
are depicted as a data matrix in which each row represents a gene and each column represents a sample. The colour coding bar above
the heat map marks the samples from the CMT-93 cell line (samples CMT93V1–3) as green, those from the liver metastases derived from
CMT-93 (samples D208-210 K, D212K) in red and those of macroscopically tumour-free liver (samples D208-210 N, D212-215 N) in blue.
Expression levels are depicted according to the colour scale presented in the top left corner. Red indicates expression levels above and
green below the median, respectively. The magnitude of deviation from the median is represented by the colour saturation. The hierarchical clustering
is visualized by the dendrogram at the top, which illustrates the degree of relatedness in gene expression
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Fig. 4 Heat map illustrating the expression signature of 32 genes related to liver metastasis development. Unsupervised analysis was performed
on the data set using our filtered gene list (119 genes associated with metastasis). Depicted are 32 representative genes which were expressed
differentially during the propagation of CMT-93 cells in the liver
Bocuk et al. BMC Cancer  (2017) 17:342 Page 9 of 15
Ta
b
le
3
O
ve
rv
ie
w
of
th
e
m
os
t
re
le
va
nt
ge
ne
s
as
so
ci
at
ed
w
ith
m
et
as
ta
si
s
du
rin
g
liv
er
co
lo
ni
sa
tio
n
(F
D
R
<
5%
)
G
en
e
En
se
m
bl
ID
G
en
e
Sy
m
bo
l
Fu
nc
tio
na
lG
en
e
G
ro
up
p-
va
lu
e
M
ea
n
in
te
ns
ity
C
M
T-
93
M
ea
n
in
te
ns
ity
liv
er
m
et
as
ta
se
s
lo
gF
C
*
lo
gF
C
^
FD
R
M
at
rix
m
et
al
lo
pe
pt
i-d
as
e
7
EN
SM
U
SG
00
00
00
18
62
3
M
M
P7
Ex
tr
ac
el
lu
la
r
M
at
rix
Pr
ot
ei
ns
1,
7
×
10
−
18
0
0,
02
72
,5
6
8,
97
11
,6
9
4,
9
×
10
−
17
8
Ke
ra
tin
20
EN
SM
U
SG
00
00
00
35
77
5
KR
T2
0
C
RC
-R
el
at
ed
G
en
es
2,
9
×
10
−
17
4
0,
81
51
,9
9
5,
8
6,
12
7,
7
×
10
−
17
2
W
nt
in
hi
bi
to
ry
fa
ct
or
1
EN
SM
U
SG
00
00
00
20
21
8
W
IF
1
W
nt
Si
gn
al
lin
g
(c
an
on
ic
al
)
3,
7
×
10
−
12
6
0,
00
20
,6
8
7,
37
12
,8
5
3,
3
×
10
−
12
4
M
at
rix
m
et
al
lo
pe
pt
i-d
as
e
9
EN
SM
U
SG
00
00
00
17
73
7
M
M
P9
Ex
tr
ac
el
lu
la
r
M
at
rix
Pr
ot
ei
ns
3,
8
×
10
−
72
0,
10
14
,1
6
5,
95
7,
92
9
×
10
−
71
C
he
m
ok
in
e
(C
-X
-C
m
ot
if)
re
ce
pt
or
4
EN
SM
U
SG
00
00
00
45
38
2
C
XC
R4
C
el
lG
ro
w
th
an
d
Pr
ol
ife
ra
tio
n
G
en
es
1,
5
×
10
−
71
0,
02
19
,2
9
7,
06
10
,5
0
3,
4
×
10
−
70
M
at
rix
m
et
al
lo
pe
pt
i-d
as
e
2
EN
SM
U
SG
00
00
00
31
74
0
M
M
P2
Ex
tr
ac
el
lu
la
r
M
at
rix
Pr
ot
ei
ns
1,
8
×
10
−
70
0,
09
27
,8
3
7,
04
8,
33
4,
2
×
10
−
69
Ep
h
re
ce
pt
or
B2
EN
SM
U
SG
00
00
00
28
66
4
EP
H
B2
C
el
lG
ro
w
th
an
d
Pr
ol
ife
ra
tio
n
G
en
es
4,
8
×
10
−
59
1,
06
10
,8
6
3,
2
3,
65
8
×
10
−
58
C
he
m
ok
in
e
(C
-X
-C
m
ot
if)
re
ce
pt
or
2
EN
SM
U
SG
00
00
00
26
18
0
C
XC
R2
C
el
lG
ro
w
th
an
d
Pr
ol
ife
ra
tio
n
G
en
es
1,
1
10
−
40
0,
04
7,
53
5,
51
7,
75
9,
7
×
10
−
40
C
ad
he
rin
11
EN
SM
U
SG
00
00
00
31
67
3
C
D
H
11
C
el
lA
dh
es
io
n
G
en
es
8,
8
×
10
−
40
0,
12
6,
32
4,
67
5,
75
7,
9
×
10
−
39
A
xi
n2
EN
SM
U
SG
00
00
00
00
14
2
A
XI
N
2
W
nt
Si
gn
al
lin
g
(c
an
on
ic
al
)
2,
2
×
10
−
39
20
,3
1
72
,1
0
1,
82
1,
87
2
×
10
−
38
In
te
gr
in
be
ta
3
EN
SM
U
SG
00
00
00
20
68
9
IT
G
B3
C
el
lA
dh
es
io
n
G
en
es
1,
6
×
10
−
33
5,
54
25
,4
8
2,
17
2,
35
1,
2
×
10
−
32
M
at
rix
m
et
al
lo
pe
pt
id
as
e
13
EN
SM
U
SG
00
00
00
50
57
8
M
M
P1
3
Ex
tr
ac
el
lu
la
r
M
at
rix
Pr
ot
ei
ns
8,
1
×
10
−
29
0,
22
7,
45
4,
43
5,
20
4,
8
×
10
−
28
G
ly
co
pr
ot
ei
n
(t
ra
ns
m
em
br
an
e)
nm
b
EN
SM
U
SG
00
00
00
29
81
6
G
PN
M
B
C
el
lA
dh
es
io
n
G
en
es
3,
9
×
10
−
27
0,
21
14
,5
0
5,
45
6,
25
2,
1
×
10
−
26
Sn
ai
lf
am
ily
zi
nc
fin
ge
r
1
EN
SM
U
SG
00
00
00
42
82
1
SN
A
I1
EM
T
Tr
an
si
tio
n
2,
9
×
10
−
26
0,
12
3,
05
3,
62
4,
66
1,
5
×
10
−
25
Pl
as
m
in
og
en
ac
tiv
at
or
,
ur
ok
in
as
e
re
ce
pt
or
EN
SM
U
SG
00
00
00
46
22
3
PL
A
U
R
C
el
lG
ro
w
th
an
d
Pr
ol
ife
ra
tio
n
G
en
es
8,
9
×
10
−
20
19
1,
38
71
,5
0
−
1,
42
−
1,
28
3,
6
×
10
−
19
M
at
rix
m
et
al
lo
pe
pt
id
as
e
3
EN
SM
U
SG
00
00
00
43
61
3
M
M
P3
Ex
tr
ac
el
lu
la
r
M
at
rix
Pr
ot
ei
ns
3,
7
×
10
−
17
0,
05
2,
70
3,
95
5,
74
1,
3
×
10
−
16
In
te
gr
in
al
ph
a
6
EN
SM
U
SG
00
00
00
27
11
1
IT
G
A
6
C
el
lA
dh
es
io
n
G
en
es
5
×
10
−
17
12
,0
3
31
,2
3
1,
36
1,
32
1,
8
×
10
−
16
M
at
rix
m
et
al
lo
pe
pt
id
as
e
10
EN
SM
U
SG
00
00
00
47
56
2
M
M
P1
0
Ex
tr
ac
el
lu
la
r
M
at
rix
Pr
ot
ei
ns
7,
6
×
10
−
17
0,
06
2,
68
3,
83
5,
37
2,
7
×
10
−
16
So
m
at
os
ta
tin
re
ce
pt
or
2
EN
SM
U
SG
00
00
00
47
90
4
SS
TR
2
C
el
lG
ro
w
th
an
d
Pr
ol
ife
ra
tio
n
G
en
es
5,
7
×
10
−
15
0,
22
1,
57
2,
19
3,
17
1,
8
×
10
−
14
Ju
n
pr
ot
o-
on
co
ge
ne
EN
SM
U
SG
00
00
00
52
68
4
JU
N
Tr
an
sc
rip
tio
n
Fa
ct
or
s
an
d
Re
gu
la
to
rs
7,
8
×
10
−
13
22
,1
3
44
,8
9
1,
01
1,
16
2,
3
×
10
−
12
Fr
iz
zl
ed
ho
m
ol
og
2
(D
ro
so
ph
ila
)
EN
SM
U
SG
00
00
00
50
28
8
FZ
D
2
W
nt
Si
gn
al
lin
g
(c
an
on
ic
al
)
1,
1
×
10
−
12
6,
88
2,
16
-1
,7
-1
,5
4
3
×
10
−
12
C
he
m
ok
in
e
(C
-C
m
ot
if)
lig
an
d
7
EN
SM
U
SG
00
00
00
35
37
3
C
C
L7
C
el
lG
ro
w
th
an
d
Pr
ol
ife
ra
tio
n
G
en
es
2,
4
×
10
−
12
0,
98
9,
98
3,
18
3,
47
6,
9
×
10
−
12
N
uc
le
ar
re
ce
pt
or
su
bf
am
ily
4,
gr
ou
p
A
,m
em
be
r
3
EN
SM
U
SG
00
00
00
28
34
1
N
R4
A
3
Tr
an
sc
rip
tio
n
Fa
ct
or
s
an
d
Re
gu
la
to
rs
3,
5
×
10
−
12
0,
16
1,
22
2,
1
3,
31
1
×
10
−
11
RA
R-
re
la
te
d
or
ph
an
re
ce
pt
or
be
ta
EN
SM
U
SG
00
00
00
36
19
2
RO
RB
2,
6
×
10
−
11
2,
57
0,
70
-1
,9
4
-1
,6
8
7
×
10
−
11
Bocuk et al. BMC Cancer  (2017) 17:342 Page 10 of 15
Ta
b
le
3
O
ve
rv
ie
w
of
th
e
m
os
t
re
le
va
nt
ge
ne
s
as
so
ci
at
ed
w
ith
m
et
as
ta
si
s
du
rin
g
liv
er
co
lo
ni
sa
tio
n
(F
D
R
<
5%
)
(C
on
tin
ue
d)
C
el
lG
ro
w
th
an
d
Pr
ol
ife
ra
tio
n
G
en
es
C
yc
lin
-d
ep
en
de
nt
ki
na
se
in
hi
bi
to
r
2A
EN
SM
U
SG
00
00
00
44
30
3
C
D
KN
2A
Tr
an
sc
rip
tio
n
Fa
ct
or
s
an
d
Re
gu
la
to
rs
1,
9
×
10
−
8
17
9,
73
91
,4
0
−
0,
98
−
0,
84
4,
4
×
10
−
8
M
at
rix
m
et
al
lo
pe
pt
id
as
e
11
EN
SM
U
SG
00
00
00
00
90
1
M
M
P1
1
Ex
tr
ac
el
lu
la
r
M
at
rix
Pr
ot
ei
ns
6,
6
×
10
−
7
12
,3
0
5,
36
−
1,
21
−
1,
19
1,
4
×
10
−
6
Et
s
va
ria
nt
4
EN
SM
U
SG
00
00
00
17
72
4
ET
V4
Tr
an
sc
rip
tio
n
Fa
ct
or
s
an
d
Re
gu
la
to
rs
9,
5
×
10
−
7
21
,6
0
10
,1
3
−
1,
1
−
0,
93
1,
9
×
10
−
6
Ly
m
ph
oi
d
en
ha
nc
er
bi
nd
in
g
fa
ct
or
1
EN
SM
U
SG
00
00
00
27
98
5
LE
F1
EM
T
Tr
an
si
tio
n
5,
3
×
10
−
5
0,
37
1,
19
1,
26
1,
69
9,
3
×
10
−
5
C
as
pa
se
3
EN
SM
U
SG
00
00
00
31
62
8
C
A
SP
3
A
po
pt
os
is
G
en
es
0,
00
02
7
48
,5
8
29
,5
5
−
0,
72
−
0,
57
0,
00
04
5
Fi
br
on
ec
tin
1
EN
SM
U
SG
00
00
00
26
19
3
FN
1
EM
T
Tr
an
si
tio
n
0,
00
08
5
10
51
,5
0
80
5,
60
−
0,
38
−
0,
74
0,
00
13
4
B
ce
ll
C
LL
/ly
m
ph
om
a
9
EN
SM
U
SG
00
00
00
38
25
6
BC
L9
W
nt
Si
gn
al
lin
g
(c
an
on
ic
al
)
0,
00
22
2
15
,5
0
19
,2
0
0,
3
0,
42
0,
00
33
6
D
ic
kk
op
f
ho
m
ol
og
2
(X
en
op
us
la
ev
is)
EN
SM
U
SG
00
00
00
28
03
1
D
KK
2
W
nt
Si
gn
al
lin
g
(c
an
on
ic
al
)
0,
02
67
1
9,
31
6,
03
−
0,
65
−
0,
50
0,
03
56
6
Lo
gF
C
*
de
sc
rib
es
ch
an
ge
s
be
tw
ee
n/
co
m
pa
rin
g
th
e
m
ea
n
in
te
ns
iti
es
ca
lc
ul
at
ed
as
th
e
lo
g
fo
ld
ch
an
ge
s
of
ba
se
2
re
fe
rr
in
g
to
th
e
TP
M
-v
al
ue
s,
lo
gF
C
^
re
pr
es
en
ts
th
e
lo
g
fo
ld
ch
an
ge
of
ba
se
2
fr
om
th
e
R
pa
ck
ag
e
Ed
ge
R
Bocuk et al. BMC Cancer  (2017) 17:342 Page 11 of 15
Specifically, MMPs, chemokine receptors, and integrins
are predominantly up-regulated in liver metastases
derived from CMT-93.
Interactions between carcinoma cells and stromal cells
play a vital role during the invasion of the new anatomic
metastatic site. Tumour cells must first traverse the base-
ment membrane and then create space for further expan-
sion. Components of the extracellular matrix (ECM)
contain a repository of growth factor molecules that can
be liberated by proteases secreted by carcinoma tissue.
Moreover, the basement membrane also plays crucial roles
in signal transduction events within carcinoma cells via
pathways initiated by integrin-mediated cell-matrix adhe-
sions, leading to alterations in cell polarity, proliferation,
invasiveness, and survival [20]. Additionally, the entry of
CRC cells into the hepatic microvasculature can also initi-
ate the pro-inflammatory cascade that results in Kupffer
cells being triggered to secrete chemokines [21]. Those
are known to up- and also down-regulate various vascular
adhesion receptors, thereby enabling adhesion of CRC
cells in the microvasculature of the fibroblasts and myofi-
broblasts, endothelial cells, adipocytes, and various bone-
marrow-derived cells – including macrophages and other
immune cells [22].
GO analysis is widely recognized as the premier tool
in the organization and functional annotation of molecu-
lar aspects of cellular systems [23]. We determined the
significant GO categories based on a threshold of signifi-
cance of p < 0.05. Our results reveal that the GO terms
inflammatory response, angiogenesis, and signal trans-
duction were the most relevant biological processes in-
volved in the propagation of CRC in the liver. Most
recently, Becht et al. reported that CRC molecular sub-
groups and micro-environmental signatures were highly
correlated [24]. More precisely, he stated that the mes-
enchymal subtype of CRC was characterized by a high
density of fibroblasts that most likely produces the che-
mokines and cytokines which favour tumour-associated
inflammation and support angiogenesis, resulting in a
poor prognosis. Looking into features of assessable in-
flammatory state in patients, Hamilton et al. were able
to link elevated serum levels of C - reactive protein
(CRP) with increased circulating pro-inflammatory cyto-
kines. Those patients with colorectal liver metastases
were attributed with shorter disease-free and overall sur-
vival following surgical resection [25]. Most recently, the
inflammatory milieu of CRC liver metastases was used
to investigate a new treatment option based on TIE2-
Fig. 5 Bar plot of GO pathways. Top 20 Gene Ontology categories from biological processes comparing the CMT-93 cell line with the liver metastases
derived thereof. GO categories are depicted and sorted by p-value. The dark grey bar indicates the number of significant genes from all genes in that
GO category (dark and light grey). Together with the light grey region of the bar, the plot summarises the total number of genes on the pathway
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expressing monocytes/macrophages (TEMs), a mye-
loid cell subset. Adopting the concept of gene trans-
fer, TEMs located in peritumoral sites and exerted an
anti-tumour effect through the release of interferon-
alpha (IFNα) [26]. Utilizing this strategy in mouse
models of CRC liver metastasis, TEMs accumulate in
the proximity of hepatic metastatic areas and the
TEM-mediated delivery of IFNα inhibits tumour
growth. In our study, we could not detect IFNα as
being deregulated to a significant level in the liver
metastases. However, there were a number of DEGs
associated with interferon (e.g. interferon-activated
gene 205 (IFI205), interferon-induced transmembrane
protein 1 (IFITM1) and interferon gamma inducible
protein 30 (IFI30)), which were not members of the
top 100 list (data not shown).
Different angiogenic factors have been related to
metastasis formation because they promote primary
tumour growth and increase the likelihood that tumour
cells come into contact with blood and thus disseminate
[27]. In particular, the liver is known to be a permissive
soil with respect to angiogenesis. The liver parenchyma
adjacent to the synchronous liver metastases provides an
angiogenically favourable environment for metastatic
tumour growth [28]. On the individual level, there was
significant correlation between primary CRCs and
matched liver metastases with respect to vascular endo-
thelial growth factor (VEGF) mRNA expression. VEGF
mRNA levels in patients with two or more liver meta-
static tumours were significantly higher than those in
patients with only solitary liver metastases [29]. To date,
oxaliplatin- and irinotecan-based chemotherapy regi-
mens combined with monoclonal antibody treatment in
the form of bevacizumab (anti-VEGF) have proved to be
efficient as first-line therapy of metastatic colorectal
cancer [30, 31].
Invasion processes are crucial to the formation of liver
metastases in CRC and regularly involve a variety of
MMPs leading to the degradation and remodelling of
the extracellular matrix (ECM) [18, 27]. CRC liver me-
tastases express MMP7 more intensely than normal liver
[32]. Our results support the notion that MMP7 is one
of the significant players enhancing invasiveness in CRC
[33–35]. It is worth noting here that targeted therapy in
this matter is difficult. There is evidence in some pre-
clinical models that MMP inhibitors (MMPIs) are effect-
ive at multiple stages of CRC tumour progression,
inhibiting both establishment and growth of primary
CRC tumours, as well as reducing metastasis in the
lungs and liver [36]. However, clinical trials with MMPIs
have been largely unsuccessful as therapeutic agents in
CRC so far. A recent study in pre-clinical mouse models
of metastatic CRC suggests that ulinastatin (an intrinsic
trypsin inhibitor) and natural polyphenol curcumin are
capable of inhibiting CRC liver metastases via modula-
tion of MMP9 and E-cadherin expression [37].
The model developed certainly proved to be suitable,
as the invasion and expansion of CMT-93 following
their injection via the portal vein leading to liver metas-
tasis was reproducible. Our results clearly support the
notion of an invasion-metastasis cascade with notable
changes to the expression profile of CMT-93 cells on en-
tering and expanding in the liver. Although we were per-
haps able to shed some light on the bigger picture, the
relative importance of distinct events, interactions, and
the molecular drive that all serve to facilitate organ-
specific colonisation will require further investigation.
Conclusions
Our work demonstrates that the gene expression in
tumour cells is clearly altered during and following the
process of metastasis. Here, bioinformatics greatly assists
in the analysis of large amounts of data derived from
RNA-seq. Through rigorous experimental planning and
sophisticated statistical analysis, we are a step closer to
elucidating the factors and processes involved during the
liver metastasis of CRC. One or more of these dysregu-
lated genes may prove to be a worthy target and enable
us effectively to switch off a CRC cell’s capacity to act as
seed in the formation of metastases. Such a develop-
ment, at best during the early stages of disease progres-
sion, for example prior to the outgrowth of tumour cells
within the target soil, could well have a markedly posi-
tive effect on the prognosis as well as overall survival of
CRC patients.
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4 Outlook
The field of transcriptomics is another step to further understanding the mechanisms in cells.
The possibilities of performing a variety of analysis strategies are rapidly increasing over time
and the newest advancements for mutation calling further support this, thus becoming more
efficient and cheaper. The three publications included in this dissertation aim at contributing
towards a better understanding of cell mechanisms, especially for cancer, by providing an
optimised standard of analysis which is up to date with current research, add the benefits
of mutation calling, typically done in Exome-Seq, and apply both on real datasets, to find
biomarkers linking to possible drug responses.
The first study assessed the use of RNA-Seq and microarray analysis. Two datasets were
used: human RC patient data metastasised into liver and cell lines from Burkitt’s lymphoma
for the microarray and RNA-Seq platform respectively. Moreover, multiple methods for
RNA-Seq analysis were compared, which resulted in the recommendation of STAR together
with RSEM, followed by edgeR and topGO.
The second study consisted of the development of Wileup, a tool for a cost-effective
identification of single nucleotide variants (SNVs) in tumour-only RNA-Seq samples. The
publication assessed the use case of checking a panel of mutations and had equal results
than state of the art tools. Furthermore, it is possible to detect unannotated variations
as well, despite increasing the chance of finding a false positive mutation over the panel
mode in Wileup, as they are not backed up with annotation data. Improvements for the
future would be the detection of RNA-editing events (Gott and Emeson, 2000), resulting
in false positive SNVs, and indels. The third publication (3.3) was an application of the
resulting pipeline from paper one on real data from mice developing metastasis in liver
from colorectal cancer. The bioinformatical approaches condensed via the pipeline revealed
essential mechanisms behind the expression of metastasis enhancing genes supporting a
better biological interpretation.
In conclusion, the presented studies in this thesis contribute to the highly ongoing
topic of transcriptomics with the focus on DEA and mutation calling in RNA-Seq. All
related findings in the RNA-Seq and Exome-Seq data would benefit from further studies and
validations. Finally, the provided software tool should be further improved and upgraded
according to future changing user requirements and technology development. Together with
the establishment of a standard analysis of RNA-Seq data as well as the newly emerging field
of mutation for RNA-Seq as an addition next to Exome-Seq, this dissertation is a valuable
 4 Outlook
addition to strategies tackling the problem of finding new biomarkers and corresponding
drug responses in the research field of cancer.
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